pvotf_10q.htm

% of ownership

Jurisdiction

Pivot Pharmaceuticals Inc.

IndUS Pharmaceuticals, Inc.

0001477932-16-014025.txt : 20161212 0001477932-16-014025.hdr.sgml : 20161212 20161209193131 ACCESSION NUMBER: 0001477932-16-014025 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 56 CONFORMED PERIOD OF REPORT: 20161031 FILED AS OF DATE: 20161212 DATE AS OF CHANGE: 20161209 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Pivot Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001464165 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0131 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-161157 FILM NUMBER: 162045045 BUSINESS ADDRESS: STREET 1: 1275 WEST 6TH AVENUE CITY: VANCOUVER STATE: A1 ZIP: V6H 1A6 BUSINESS PHONE: 604 805 7783 MAIL ADDRESS: STREET 1: 1275 WEST 6TH AVENUE CITY: VANCOUVER STATE: A1 ZIP: V6H 1A6 FORMER COMPANY: FORMER CONFORMED NAME: Neurokine Pharmaceuticals Inc. DATE OF NAME CHANGE: 20090514 10-Q 1 pvotf_10q.htm FORM 10-Q pvotf_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended October 31, 2016

o TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

Commission File Number 333-161157

PIVOT PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)

British Columbia

N/A
(State or other jurisdiction of incorporation or organization)

(IRS Employer Identification No.)

1275 West 6th Avenue, Vancouver, British Columbia, Canada

V6H 1A6
(Address of principal executive offices)

(Zip Code)

(604) 805-7783
(Registrant’s telephone number, including area code)

N/A
(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x YES o NO

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x YES o NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer
o
Smaller reporting company
x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) o YES x NO

APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Exchange Act after the distribution of securities under a plan confirmed by a court. o YES o NO

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

75,647,100 common shares issued and outstanding as of December 9, 2016.

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION

Item 1.
Financial Statements.
3
Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations.
15
Item 3.
Quantitative and Qualitative Disclosure About Market Risk.
23
Item 4.
Controls and Procedures.
23
PART II – OTHER INFORMATION

Item 1.
Legal Proceedings.
24
Item 1A.
Risk Factors.
24
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds.
24
Item 3.
Defaults Upon Senior Securities.
24
Item 4.
Mine Safety Disclosures.
24
Item 5.
Other Information.
24
Item 6.
Exhibits.
25
SIGNATURES.
27

2
Table of Contents

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements

Our unaudited interim condensed consolidated financial statements for the period ended October 31, 2016 form part of this quarterly report. All currency references in this report are to U.S. dollars unless otherwise noted. This financial information, in the opinion of management, includes all adjustments consisting of normal recurring entries necessary for the fair presentation of such data. The results of operations for the three and nine month periods ended October 31, 2016 are not necessarily indicative of results to be expected for any subsequent period.

3
Table of Contents

PIVOT PHARMACEUTICALS INC.

Condensed Consolidated Financial Statements

(Expressed in U.S. dollars)

Period ended October 31, 2016 (unaudited) and January 31, 2016

4
Table of Contents

PIVOT PHARMACEUTICALS INC.

Condensed Consolidated Balance Sheets

(Expressed in U.S. dollars)

October 31,
2016
$

January 31,
2016
$

(unaudited)

Assets

Current assets

Cash

206,575

71,639

Prepaid and other current assets

19,211

31,576

Total current assets

225,786

103,215

Security deposit

2,900

2,900

Total assets

228,686

106,115

Liabilities and Stockholders’ Deficit

Current liabilities

Accounts payable and accrued liabilities

774,725

397,482

Due to related parties (Note 9)

25,972

37,622

Convertible debenture, net of discount (Note 4)

142,588

–

Derivative liability (Note 5)

447,115

–

Total liabilities

1,390,400

435,104

Stockholders’ Deficit

Common stock: Unlimited shares authorized, without par value, 75,622,100 and 74,722,100 shares issued and outstanding, respectively

7,324,881

7,054,499

Common stock issuable (Note 6)

1,697

16,206

Additional paid-in capital

10,661,752

6,174,601

Accumulated other comprehensive income

635,654

745,251

Accumulated deficit

(19,785,698 )

(14,319,546 )

Total stockholders’ deficit

(1,161,714 )

(328,989 )

Total liabilities and stockholders’ deficit

228,686

106,115

(The accompanying notes are an integral part of these condensed consolidated financial statements)

5
Table of Contents

PIVOT PHARMACEUTICALS INC.

Condensed Consolidated Statements of Operations

(Expressed in U.S. dollars)

Three Months
Ended
October 31,
2016
$

Three Months
Ended
October 31,
2015
$

Nine Months
Ended
October 31,
2016
$

Nine Months
Ended
October 31,
2015
$

(unaudited)

(unaudited)

(unaudited)

(unaudited)

Revenue

–

–

–

–

Expenses

Depreciation and amortization

–

86

–

269

Foreign exchange loss

60,658

4,367

138,017

8,733

General and administrative

71,301

(8,264 )

1,045,722

866,505

Management fees (Note 9)

548,407

(116,405 )

3,917,354

2,298,813

Professional fees

9,938

128,058

100,421

355,727

Total expenses

690,304

7,842

5,201,514

3,530,047

Loss from operations

(690,304 )

(7,842 )

(5,201,514 )

(3,530,047 )

Other income (expense)

Amortization of discount on convertible debenture

(48,672 )

–

(48,672 )

–

Interest expense

(3,612 )

–

(3,612 )

–

(Loss) gain on change in fair value of derivative liabilities

(212,354 )

–

(212,354 )

14,958

Total other income (expense)

(264,638 )

–

(264,638 )

14,958

Net loss

(954,942 )

(7,842 )

(5,466,152 )

(3,515,089 )

Other comprehensive income (loss)

Foreign currency translation adjustment

(40,569 )

142,447

109,597

(261,299 )

Net comprehensive income (loss)

(995,511 )

134,605

(5,356,555 )

(3,776,388 )

Net loss per share, basic and diluted

(0.01 )

(0.00 )

(0.07 )

(0.05 )

Weighted average shares outstanding – basic and diluted

75,613,498

85,570,289

75,212,555

76,886,477

(The accompanying notes are an integral part of these condensed consolidated financial statements)

6
Table of Contents

PIVOT PHARMACEUTICALS INC.

Condensed Consolidated Statements of Cash Flows

(Expressed in U.S. dollars)

Nine Months
Ended
October 31,
2016
$

Nine Months
Ended
October 31,
2015
$

(unaudited)

(unaudited)

Operating activities

Net loss

(5,466,152 )

(3,515,089 )
Adjustments to reconcile net loss to net cash used in operating activities:

Amortization of discount on convertible debenture

48,672

–

Depreciation

–

268

Fair value of stock options vested

4,300,354

–

Loss (gain) on change in fair value of derivative liabilities

212,354

(14,958 )
Stock issued for services

256,382

3,310,773

Changes in operating assets and liabilities:

Prepaids and other current assets

5,938

(15,812 )
Accounts payable and accrued liabilities

366,124

71,000

Net cash used in operating activities

(276,328 )

(163,818 )

Financing activities

Proceeds from convertible debenture

381,350

–

Proceeds from stock to be issued

–

240,000

Proceeds from related party advances

16,500

1,075

Net cash provided by financing activities

397,850

241,075

Effects of exchange rate changes on cash

13,414

65,544

Increase in cash

134,936

142,801

Cash – beginning of period

71,639

838

Cash – end of period

206,575

143,639

Non-cash investing and financing activities

Debt discounts on convertible debt

284,184

–

Supplemental disclosures:

Interest paid

–

–

Income tax paid

–

–

(The accompanying notes are an integral part of these condensed consolidated financial statements)

7
Table of Contents

PIVOT PHARMACEUTICALS INC.

Notes to the Condensed Consolidated Financial Statements

Period ended October 31, 2016

(Expressed in U.S. dollars)

1. Nature of Operations and Continuance of Business

Pivot Pharmaceuticals Inc. (the “Company”) was incorporated in British Columbia under the Business Corporations Act on June 10, 2002. On April 7, 2015, the Company changed its name from Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc. The Company is in the business of developing and commercializing therapeutic pharmaceutical products, focused on the strategy of identifying new therapeutic treatments to address unmet medical needs in women’s health.

These consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As of October 31, 2016, the Company has not earned any revenue, has a working capital deficit of $1,164,614 and an accumulated deficit of $19,785,698. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Significant Accounting Policies

(a) Basis of Presentation

The consolidated financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in U.S. dollars. The Company’s fiscal year-end is January 31.

(b) Use of Estimates

The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

(c) Interim Financial Statements

These interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial position, results of operations and cash flows for the periods shown. The condensed consolidated results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Certain disclosures and financial information have been condensed in accordance with generally accepted accounting principles in the United States.

8
Table of Contents

PIVOT PHARMACEUTICALS INC.

Notes to the Condensed Consolidated Financial Statements

Period ended October 31, 2016

(Expressed in U.S. dollars)

2. Significant Accounting Policies (continued)

(d) Basis of Consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidating entities include:

% of ownership

Jurisdiction

Pivot Pharmaceuticals Inc.

Parent

Canada

IndUS Pharmaceuticals, Inc.

100%

USA

(e) Loss Per Share

The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method for all exercisable options and warrants and the if-converted method for all outstanding convertible debentures. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. At October 31, 2016 and 2015, the Company had 8,705,847 and zero potentially dilutive shares, respectively.

(f) Financial Instruments and Fair Value Measures

ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2: Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3: Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, amounts receivable, accounts payable and accrued liabilities, due to related parties and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

9
Table of Contents

PIVOT PHARMACEUTICALS INC.

Notes to the Condensed Consolidated Financial Statements

Period ended October 31, 2016

(Expressed in U.S. dollars)

2. Significant Accounting Policies (continued)

(g) Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.

3. Property and Equipment

Cost
$

Accumulated amortization
$

October 31,
2016
Net carrying
value
$
(unaudited)

January 31,
2016
Net carrying
value
$

Office furniture and equipment

1,628

1,628

–

–

Depreciation expense included as a charge to income was $nil and $268 for the nine months ended October 31, 2016 and 2015, respectively.

4. Convertible Debenture

On September 30, 2016, the Company issued a convertible debenture with a non-related party for $500,000 Canadian Dollars ($380,411 US Dollars at September 30, 2016) (“Initial Advance”). The debenture is secured under a General Security Agreement, bears interest at 8% per annum and matures on the earlier of:

· The date the lender demands repayment of principal and interest following an event of default,
· The date of a dissolution event,
· The date of a liquidity event, and
· March 30, 2017.

The Company may request one or more additional advances of up to an aggregate amount of $1,000,000 Canadian Dollars (“Additional Advances”) provided that the aggregate amount under the convertible debenture does not exceed $1,500,000 Canadian Dollars.

The note, including the Initial Advance and any Additional Advances, is convertible into common shares at a conversion price equal to the average closing market price of the Company’s common stock during the five day period leading up to the conversion date. The Company recorded the conversion feature of the convertible debenture as a derivative liability at an estimated fair value of $221,158 with a corresponding discount to the convertible debenture (Note 5).

Pursuant to the convertible loan agreement, the Company issued 434,622 share purchase warrants to which the lender may acquire an interest in the Company equal to 12% of the maximum principal amount outstanding at any time at a price of $0.10, which equates to the ten day average trading price of the Company’s common stock determined as at September 30, 2016. The Company calculated the 434,622 share purchase warrants based on the maximum outstanding principal balance on the convertible loan as of September 30, 2016. The Company recorded the share purchase warrant at an estimated fair value of $20,154 with a corresponding discount to the convertible debenture (Note 8).

10
Table of Contents

PIVOT PHARMACEUTICALS INC.

Notes to the Condensed Consolidated Financial Statements

Period ended October 31, 2016

(Expressed in U.S. dollars)

4. Convertible Debenture (continued)

As of October 31, 2016, the carrying value of the convertible debenture is $191,215 Canadian Dollars ($142,588 US Dollars at October 31, 2016) (January 31, 2016 - $nil) with accrued interest $2,533 (January 31, 2016 - $nil). As of October 31, 2016, the fair value of the conversion option derivative liability is $447,115 (January 31, 2016 - $nil).

5. Derivative Liability

Derivative liability consists of convertible debenture with variable conversion price (Note 4). The fair value of derivative liability as at October 31, 2016 and January 31, 2016 is as follows:

October 31,
2016
$

January 31,
2016
$

September 2016 convertible debenture

447,115

–

447,115

–

The fair value of derivative financial liability was determined using the Black-Scholes option pricing model, using the following assumptions:

Expected
Volatility

Risk-free
Interest Rate

Expected
Dividend Yield

Expected Life
(in years)

As at issuance date:

September 2016 convertible debenture

296 %

0.45 %

0 %

0.50

As at October 31, 2016:

September 2016 convertible debenture

311 %

0.51 %

0 %

0.41

6. Common Stock

(a) On February 10, 2016, the Company issued 100,000 shares of common stock to service providers for services provided valued at $68,000. The value of the common stock was based on the market price of the stock on the date of issuance.

(b) On February 29, 2016, March 31, 2016, May 2, 2016, May 31, 2016, June 28, 2016, August 2, 2016 and August 30, 2016, the Company issued 25,000 shares of common stock on each of these dates to the Company’s CEO as monthly compensation valued at $15,000, $13,750, $7,500, $6,000, $4,875, $3,757 and $3,250, respectively. The value of the common stock was based on the market price of the stock on the date of issuance.

(c) In June 2016, 600,000 shares of common stock were issued to service providers and valued at $144,500 based on the market price of the stock on the dates of issuances.

(d) On July 31, 2016, 25,000 shares of common stock, valued at $3,750, previously held in escrow were released to a member of the Company’s Scientific Advisory Board (“SAB member”). The value of the common stock was based on the market price of the stock on the date of issuance. On October 31, 2016, common stock with a fair value of $1,697 remains issuable to this SAB member.

11
Table of Contents

PIVOT PHARMACEUTICALS INC.

Notes to the Condensed Consolidated Financial Statements

Period ended October 31, 2016

(Expressed in U.S. dollars)

7. Stock Options

Effective December 30, 2015, the Company adopted a stock option plan. Under this plan, the Company may grant options to its directors, officers, employees and consultants up to an amount as determined by the Company and will be no more than a percentage of its outstanding common stock as may be required by the stock exchange the Company is listed with. The exercise price of the stock options will be determined by the Company and will be no less than any minimum exercise price as may be required by the stock exchange the Company is listed with.

The following table summarizes the continuity of the Company’s stock options:

Number
of Options

Weighted
Average
Exercise Price
(US$)

Weighted Average
Remaining
Contractual
Life (years)

Aggregate
Intrinsic
Value
(US$)

Outstanding, January 31, 2015

80,000

0.05

–

–

Granted

6,200,000

0.10

4.1

4,930,000

Expired

(80,000 )

(0.05 )

–

–

Outstanding, January 31, 2016

6,200,000

0.10

4.1

4,930,000

Granted

7,279,000

0.70

4.3

–

Forfeited

(2,000,000 )

(0.10 )

–

–

Outstanding, October 31, 2016

11,479,000

0.48

4.2

36,000

The fair value of stock-based compensation expense was estimated using the Black-Scholes option pricing model and the following assumptions:

Expected
Volatility

Risk-free
Interest Rate

Expected
Dividend Yield

Expected Life
(in years)

200,000 options expiring on November 30, 2020

400 %

1.16 %

0 %

4.1

7,250,000 options expiring on February 22, 2021

393 %

1.16 %

0 %

4.3

29,000 options expiring on May 2, 2021

393 %

1.16 %

0 %

4.5

Additional information regarding stock options as of October 31, 2016, is as follows:

Options
Outstanding

Option
Exercisable

Exercise
Price
$

Expiry
Date

200,000

100,000

0.25

November 30, 2020

4,000,000

4,000,000

0.10

December 14, 2020

7,250,000

5,437,500

0.70

February 22, 2021

29,000

26,000

0.34

May 2, 2021

11,479,000

9,563,500

$83,068 of stock-based compensation have yet to be recognized and will be recognized in future periods.

12
Table of Contents

PIVOT PHARMACEUTICALS INC.

Notes to the Condensed Consolidated Financial Statements

Period ended October 31, 2016

(Expressed in U.S. dollars)

8. Share Purchase Warrant

The following table summarizes the continuity of share purchase warrant:

Number of
Warrants

Weighted
Average
Exercise
Price
$

Balance, January 31, 2016

–

–

Granted

434,622

0.10

Balance, October 31, 2016

434,622

0.10

As at October 31, 2016, the following share purchase warrant was outstanding:

Number of
Warrants

Exercise
Price
$

Expiry Date

434,622

0.10

March 30, 2017

Pursuant to the convertible debenture (Note 4), the Company will be required to issue additional share purchase warrants on any Additional Advances to which the lender may acquire an interest in the Company equal to 12% of the maximum principal amount outstanding.

9. Related Party Transactions

As at October 31, 2016, the Company owed $4,694 (January 31, 2016 - $800) to a director of the Company, which is unsecured, non-interest bearing, and due on demand.

As at October 31, 2016, the Company owed $16,721 (January 31, 2016 – Receivable of $866) to the Company’s Chief Executive Officer.

As at October 31, 2016, the Company owed $4,557 (January 31, 2016 - $37,622) to related parties related to stock options to be granted pursuant to the Agreement and Plan of Merger and Acquisition Agreement dated as of November 4, 2015 between the Company and IndUS (Note 2).

On April 15, 2015, the Company issued 2,000,000 shares of common stock to an officer for services provided. This $191,356 of compensation expense has been included in professional fees.

PIVOT PHARMACEUTICALS INC.

Notes to the Condensed Consolidated Financial Statements

Period ended October 31, 2016

(Expressed in U.S. dollars)

10. Fair Value Measurements

The Company’s financial liabilities carried at fair value measured on a recurring basis as of October 31, 2016 and January 31, 2016, consisted of the following:

Total fair
value at
October 31,
2016

Quoted
prices in
active markets
(Level 1)

Significant
other
observable
inputs
(Level 2)

Significant unobservable
inputs
(Level 3)

Derivative liability ⁽¹⁾

$ 447,115

$ -

$ 447,115

$ -

Total fair
value at
January 31,
2016

Quoted
prices in active markets
(Level 1)

Significant
other observable inputs
(Level 2)

Significant unobservable
inputs
(Level 3)

Derivative liability ⁽¹⁾

$ -

$ -

$ -

$ -

(1) Derivative liability amounts are due to the embedded derivatives of convertible debenture issued by the Company and are calculated using the Black Scholes pricing model (Note 5).

The Company has no financial assets carried at fair value.

11. Subsequent Events

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on such evaluation, no events occurred that required disclosure.

14
Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements

This report on Form 10-Q contains certain forward-looking statements. All statements other than statements of historical fact are “forward-looking statements” for purposes of these provisions, including any projections of earnings, revenues, or other financial items; any statements of the plans, strategies, and objectives of management for future operation; any statements concerning proposed new products, services, or developments; any statements regarding future economic conditions or performance; statements of belief; and any statement of assumptions underlying any of the foregoing. Such forward-looking statements are subject to inherent risks and uncertainties, and actual results could differ materially from those anticipated by the forward-looking statements.

These forward-looking statements involve significant risks and uncertainties, including, but not limited to, the following: competition, promotional costs and the risk of declining revenues. Our actual results could differ materially from those anticipated in such forward-looking statements as a result of a number of factors. These forward-looking statements are made as of the date of this filing, and we assume no obligation to update such forward-looking statements. The following discusses our financial condition and results of operations based upon our unaudited financial statements which have been prepared in conformity with accounting principles generally accepted in the United States. It should be read in conjunction with our financial statements and the notes thereto included elsewhere herein.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our financial statements are stated in U.S. Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles.

In this quarterly report, unless otherwise specified, all dollar amounts are expressed in U.S. Dollars (US$) and all references to “common shares” refer to the common shares in our capital stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Pivot Pharmaceuticals Inc., unless otherwise indicated.

General Overview

We are a development stage pharmaceutical company. We were incorporated in the Province of British Columbia, Canada under the name “649186 B.C. Ltd.”, on June 10, 2002. On September 9, 2003, we changed our name to “Xerxes Health Corp.” and on June 26, 2007, we changed our name to “Neurokine Pharmaceuticals Inc.”.

Effective June 4, 2014, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we increased our authorized share capital from 500,000,000 common shares without par value to an unlimited number of common shares without par value. The increase of authorized capital was approved by our stockholders at the annual and special meeting held on June 3, 2014.

On September 26, 2014, our company held a special meeting of stockholders to approve the removal of our company's Pre-Existing Company Provisions, the cancellation of our current Articles and the adoption of new Articles and to approve a reverse stock split on the basis of up to one new common stock for every 100 old common stock.

15
Table of Contents

Effective October 8, 2014, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we removed our Pre-Existing Company Provisions.

Effective April 7, 2015, we filed with the British Columbia Registrar of Companies a Form 11, Notice of Alteration, wherein we changed our name to "Pivot Pharmaceuticals Inc.".

Effective at the opening of trading on April 20, 2015, as approved by FINRA, our company effected a reverse stock split of our issued and outstanding common shares on the basis of 10 old common stock for 1 new common stock.

On November 20, 2015, we completed the acquisition of IndUS Pharmaceuticals, Inc. (“IndUS”), a Delaware corporation, pursuant to an Agreement and Plan of Merger and Acquisition Agreement dated as of November 4, 2015 among our company, Pivot Pharma U.S. Inc., our wholly owned subsidiary, IndUS and Sindu Research Laboratories Pvt Ltd. As consideration for the purchase, we issued 4,512,500 shares of common stock on November 23, 2015 and 237,500 shares of common stock on December 4, 2015. We will also be granting 41,833 stock options pursuant to the Agreement and Plan of Merger. As part of the acquisition, we appointed Dr. Pravin Chaturvedi as our new Chief Executive Officer and Director.

IndUS is an emerging United States-India cross-border pharmaceutical company located in the Greater Boston area, which is engaged in conducting research and development activities for advancing novel therapeutics in the areas of oncology, infectious diseases and diabetes.

Our principal executive office is located at 1275 West 6th Avenue, Vancouver, B.C. Canada V6H 1A6, with another office at 25 Olympia Avenue, Suite K-300, Woburn, MA 01801, USA. Our telephone number is (978) 973-5271.

Our Current Business

We are a development stage biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceutical products, focused on the strategy of identifying new therapeutic treatments to address unmet medical needs in women’s health including but not limited to urological and/or gynecological disturbances; and advancing novel anticancer drug candidates to provide new treatment options for metastatic cancers in women that do not have adequate treatment options or have poor response to existing treatment options due to inherent or acquired mutations. Our research and development activities are focused on i) advancing novel drug candidates for the treatment of women’s cancers including, but not limited to metastatic endometrial cancer and triple-negative breast cancer, which have limited treatment options; and ii) leveraging novel drug delivery treatment options to allow ‘targeted’ delivery of drugs to address women’s health needs in urological and/or gynecological indications, and iii) opportunistically in-licensing later-stage drug candidates to augment our drug pipeline. Where appropriate, we intend to depart from these strategies to opportunistically acquire additional novel treatment options to address unmet or under-served medical needs in women’s health.

Our business model currently includes the following activities:

· identifying novel drug delivery technologies that will allow targeted drug delivery for drugs;
· securing and developing intellectual property rights to such products;
· conducting appropriate laboratory tests and clinical trials;
· advancing novel drug candidates to treat women’s cancers from our acquisition of IndUS to support Investigational New Drug application to allow first-in-human trials;
· opportunistically acquiring later-stage drug candidates that provide new treatment options to address unmet medical needs in women’s health in cancer and lower urinary tract symptoms; and
· establishing partnerships with large and specialty pharmaceutical companies and/or biotechnology companies to collaboratively develop and/or commercialize our products.

16
Table of Contents

One of our areas of focus includes developing therapeutic applications for existing drugs using novel delivery technologies for the treatment of diseases and conditions specific to cancer and/or urological disturbances in women. The diseases and conditions that are the subject of our research and development program include addressing resistant cancers affecting women’s health and developing new treatment options using novel drugs and/or novel delivery approaches to address oncological and urological conditions such as various gynecological and breast cancers as well as lower urinary tract symptoms such as overactive bladder. Our current pipeline addresses the therapeutic areas of cancer and lower urinary tract symptoms (LUTS):

· Metastatic endometrial cancer (PVT-005)
· Triple-negative breast cancer (PVT-006)
· Lower urinary tract symptoms including filling and voiding issues (PVT-002)

PVT-005 and PVT-006 are novel and patented anticancer small molecule drug candidates acquired through the acquisition of IndUS. These molecules are novel DNA damage response inhibitors and belong to the chemical class of pyrrolobenzodiazepine dimers (PBDs). These molecules have shown preclinical activity in cancers that have mutations in their tumor suppression and/or DNA repair abilities and have shown ‘synthetic lethality’ when dosed as monotherapy in such resistant cancers and/or in combination with standard-of-care drugs that are used in chemotherapeutic regimens for such patients. PVT-005 and PVT-006 have shown excellent activity in tumor cells that have genetic or epigenetic mutations in DNA mismatch repair (mlh1, MSH2), tumor suppression functions (p53, PTEN) and/or homologous recombination (HR) functions. They have shown significant synergies with platinum-based drugs such as cisplatin, and other drugs like topoisomerase II and I inhibitors (doxorubicin and camptothecin, respectively) and receptor tyrosine kinase (RTK) inhibitors – all or some of which are part of standard-of-care chemotherapeutic regimens to treat ovarian, breast, colorectal, non-small cell lung and other cancers that affect women’s health.

Our research and development strategy is focused on developing novel treatment options to address various unmet medical needs in women’s health, including but not limited to 1) urological and gynecological disturbances such as lower urinary tract symptoms; and 2) addressing unmet or under-served medical needs in women’s cancers such as metastatic endometrial or triple-negative breast cancer that have inherent or acquired mutations rendering them resistant to existing treatment options and represent orphan drug designation opportunities.

Our Research and Development Strategy

Our management team has implemented a business-minded and cost-conscious approach to product research and development by focusing on development of novel therapies to address unmet needs in women’s health. Our research and development strategy will develop novel delivery options for new and/or existing drugs to address needs in women’s health as well as advance some of its patented and proprietary novel anticancer drugs in gynecological and/or breast cancers through its recent acquisition of IndUS.

In order for a drug to be successful, it must be both efficacious and acceptably safe. Before a drug may be commercially marketed, it must be scrutinized and approved by applicable health authorities (such as the Food and Drug Administration (“FDA”) in the United States) in each country or jurisdiction where it is sought to be sold. In pharmaceutical research and development, clinical trials are conducted to allow safety and efficacy data to be collected for new drugs or devices. Health authorities then scrutinize the clinical trial results and determine, based on the results, whether a drug may be sold to the public. Similarly, clinical trials may only take place once satisfactory information has been gathered on the quality of the product and its non-clinical safety, and approval to conduct the trials has been granted by the health authority in the country where the trial is scheduled to take place.

Clinical trials involving new drugs are commonly classified into four phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug-development process will normally proceed through all four phases over many years. If the drug successfully passes through Phases I, II and III, it will usually be approved by the national regulatory authority for use in the general population. Phase IV trials are ‘post-approval’ studies. Due to the considerable cost that may be required to complete a full series of clinical trials, the burden of paying for all the necessary people and services is usually borne by the sponsor, who may be the pharmaceutical or biotechnology company that developed the drug that is the subject of the study. Since the diversity of roles may exceed the resources of the sponsor, clinical trials are often managed by outsourced partners such as contract research organizations. Furthermore, approval rates for new drugs at each clinical trial stage are prohibitively low, which may require the sponsor to finance additional trials or abandon the drug under development altogether.

17
Table of Contents

Our research and development strategy includes the development of novel anticancer drugs targeting subsets of women’s cancer patients that have endometrial, triple-negative breast and/or ovarian cancer, to explore the opportunity of securing an orphan drug designation (intended for patient populations <200,000 in the US). Since our anticancer portfolio has novel drugs that will require the conduct of nonclinical and clinical studies for new molecular entities (NMEs); we will also use targeted delivery options for approved (generic) drugs to avoid the higher cost of repeating one or more pre-clinical or clinical, safety, pharmacokinetic or other tests by applying novel drug delivery approaches to get targeted delivery of drugs and get a quicker time to market by leveraging a US regulatory pathway termed 505b2 applications. In doing so, a company may reduce the time required to complete the necessary research and development activities, which can typically take in excess of ten years, by more than half, as well as reduce the corresponding development costs.

Our recent acquisition of Greater Boston-based IndUS has provided us with a portfolio of novel, patented and proprietary, novel anticancer drug candidates from multiple chemical classes of molecules referred to as pyrrolobenzodiazepine dimers (PBDs). These molecules have shown excellent anticancer potential during their initial biological testing conducted at the National Cancer Institute in Bethesda, MD. Subsequent to their initial biological evaluation, chemical scale-up and formulation studies were conducted to evaluate their pharmacokinetics in rats and two novel and patented pyrrolobenzodiazepine dimers were prioritized for advancement through preclinical studies to support first-in-human studies. PVT-005 and PVT-006 provide novel treatment options in combination with existing chemotherapeutic regimens to address unmet medical needs in women’s cancers. Our initial focus for PVT-005 is in patients with metastatic endometrial cancer, which harbors genomic mutations in DNA replication and repair pathways that render the cancer resistant to many existing chemotherapy options. It is estimated that approximately 50,000 women in the United States have metastatic endometrial cancer that would become eligible for new therapy options following their initial treatments and PVT-005 will be added to the standard chemotherapeutic regimen(s) that will be used to treat metastatic endometrial cancer. Similarly, PVT-006, a novel and patented pyrrolobenzodiazepine dimer, distinct from PVT-005, has been identified as a lead candidate to address unmet medical needs of women with triple-negative breast cancer. Triple-negative breast cancer is a very aggressive form of breast cancer that affects younger women, predominantly of African-American descent. It is estimated that approximately 170,000 women in the United States have triple-negative breast cancer. Five different molecular subtypes of triple-negative breast cancer have been identified and the basal-like subtype of triple-negative breast cancer (BL-TNBC) affects up to 40,000 women in the United States. PVT-006 is more likely to be effective in combination with existing anticancer agents, in basal-like triple-negative breast cancer subtype due to their mutations in DNA repair and replication pathways, which PVT-006 targets as its mechanism of action.

Preclinical safety studies will be conducted over the next 12 months to advance at least one of these candidates to an IND-stage to allow initiation of clinical studies in these highly unmet medical needs in women’s cancer.

Results of Operations

The following summary of our results of operations should be read in conjunction with our financial statements for the period ended October 31, 2016, which are included herein.

Our operating results for the three and nine months ended October 31, 2016 and 2015 are summarized as follows:

Three Months Ended

Nine Months Ended

October 31,

October 31,

2016

2015

2016

2015

Revenue

$ Nil

$ Nil

$ Nil

$ Nil

Depreciation

$ Nil

$ 86

$
Nil

$ 269

Foreign exchange (gain) loss

$ 60,658

$ 4,367

$ 138,017

$ 8,733

General and administrative

$ 71,301

$ (8,264 )

$ 1,045,722

$ 866,505

Management fees

$ 548,407

$ (116,405 )

$ 3,917,354

$ 2,298,813

Professional fees

$ 9,938

$ 128,058

$ 100,421

$ 355,727

Total Other (Income) Expenses

$ 264,638

$ -

$ 264,638

$ (14,958 )
Net Income (Loss)

$ (954,942 )

$ (7,842 )

$ (5,466,152 )

$ (3,515,089 )

18
Table of Contents

For the three months ended October 31, 2016, our net loss increased by $947,100 as compared to the three months ended October 31, 2015. During the three months ended October 31, 2015, expenses decreased as a result of reversal of management and consulting fees previously recognized on common stock issued for services upon cancellation of such common stock during the period. For the nine months ended October 31, 2016, our net loss increased by $1,951,063 as compared to the nine months ended October 31, 2015. Our loss increased primarily due to 7,250,000 stock options granted to officers, directors and consultants in 2016, which increased general and administrative expenses and management fees.

Revenue

We have not earned any revenues since our inception and we do not anticipate earning revenues in the upcoming quarter.

Liquidity and Financial Condition

Working Capital

At

At

October 31,

January 31,

2016

2016

Current Assets

$ 225,786

$ 103,215

Current Liabilities

$ 1,390,400

$ 435,104

Working Capital (Deficit)

$ (1,164,614 )

$ (331,889 )

Our total current assets as of October 31, 2016 were $225,786 as compared to total current assets of $103,215 as of January 31, 2016. The increase was primarily due to proceeds from convertible debenture received during the period. Our total current liabilities as of October 31, 2016 were $1,390,400 as compared to total current liabilities of $435,104 as of January 31, 2016. The increase in current liabilities was primarily attributed to the accrual of management fees pursuant to management agreements as well as the issuance of short-term convertible debenture during the period.

Cash Flows

Nine Months Ended

October 31,

2016

2015

Net Cash Used In Operating Activities

$ (276,328 )

$ (163,818 )
Net Cash Provided By Financing Activities

$ 397,850

$ 241,075

Effects of Exchange Rate Changes on Cash

$ 13,414

$ 65,544

Increase in Cash During the Period

$ 134,936

$ 142,801

Operating Activities

During the nine months ended October 31, 2016, our cash used by operating activities increased by $112,510 when compared to cash used in operating activities during the nine months ended October 31, 2015. The increase in cash used for operating activities was a result of payments made for obligations due, including management fees, professional fees, rent and transfer agent costs.

Investing Activities

We did not have any investing activities during the nine months ended October 31, 2016 and 2015.

19
Table of Contents

Financing Activities

During the nine months ended October 31, 2016, we received $397,850 (2015 - $241,075) in cash from financing activities.

We will require additional funds to fund our budgeted expenses over the next 12 months. These funds may be raised through equity financing, debt financing, or other sources, which may result in further dilution in the equity ownership of our shares. There is still no assurance that we will be able to maintain operations at a level sufficient for an investor to obtain a return on his investment in our common stock. Further, we may continue to be unprofitable. We need to raise additional funds in the immediate future in order to proceed with our budgeted expenses.

Specifically, we estimate our operating expenses and working capital requirements for the next 12 months to be as follows:

Estimated
Expenses

Description

($)

Research and Development Costs:

Studies and manufacture of active product ingredient

5,125,000

IND filing

1,000,000

R&D headcount

1,250,000

Sales and Marketing Costs:

Entertainment and promotion

24,000

Investor relations

60,000

Literature

11,600

Travel

60,000

Operating Expenses:

Director fees

160,000

Insurance

40,000

Office

21,200

Office and laboratory lease

30,000

Professional fees

143,000

Public company expenses

52,500

Salaries and benefits

898,523

Telephone and internet

6,000

Vehicles and transportation

6,000

Total:

8,887,823

Based on our planned expenditures, we will require additional funds of approximately $8.9 million to proceed with our business plan over the next 12 months. If we secure less than the full amount of financing that we require, we will not be able to carry out our complete business plan and we will be forced to proceed with a scaled back business plan based on our available financial resources.

Inflation

The amounts presented in the consolidated financial statements do not provide for the effect of inflation on our operations or financial position. The net operating losses shown would be greater than reported if the effects of inflation were reflected either by charging operations with amounts that represent replacement costs or by using other inflation adjustments.

20
Table of Contents

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to stockholders.

Critical Accounting Policies

The discussion and analysis of our consolidated financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with the accounting principles generally accepted in the United States of America. Preparing consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. These estimates and assumptions are affected by management’s application of accounting policies. We believe that understanding the basis and nature of the estimates and assumptions involved with the following aspects of our consolidated financial statements is critical to an understanding of our consolidated financial statements.

Use of Estimates

The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Our company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities, and deferred income tax asset valuation allowances. Our company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by our company may differ materially and adversely from our company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Long-lived Assets

In accordance with ASC 360, “Property, Plant and Equipment”, our company tests long-lived assets or asset groups for recoverability when events or changes in circumstances indicate that their carrying amount may not be recoverable. Circumstances which could trigger a review include, but are not limited to: significant decreases in the market price of the asset; significant adverse changes in the business climate or legal factors; accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction of the asset; current period cash flow or operating losses combined with a history of losses or a forecast of continuing losses associated with the use of the asset; and current expectation that the asset will more likely than not be sold or disposed significantly before the end of its estimated useful life. Recoverability is assessed based on the carrying amount of the asset and its fair value, which is generally determined based on the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset, as well as specific appraisal in certain instances. An impairment loss is recognized when the carrying amount is not recoverable and exceeds fair value.

Stock-Based Compensation

Our company records stock-based compensation in accordance with ASC 718, Compensation – Stock-Based Compensation, using the fair value method. All transactions in which goods or services are the consideration received for the issuance of equity instruments are accounted for based on the fair value of the consideration received or the fair value of the equity instrument issued, whichever is more reliably measurable.

21
Table of Contents

Financial Instruments and Fair Value Measures

ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1 - Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2 - Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3 - Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

Our company’s financial instruments consist principally of cash, accounts payable and accrued liabilities and amounts due to related parties. Pursuant to ASC 820, the fair value of cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets and derivative liabilities is determined based on “Level 2” inputs, as determined by observable market data. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

Foreign Currency Translation

The functional currency of our parent entity, Pivot Pharmaceuticals Inc., is the Canadian dollar and the functional currency of our subsidiary is the US dollar. Our company’s presentation currency is the US dollar.

Monetary assets and liabilities are translated using the exchange rate prevailing at the consolidated balance sheet date. Non-monetary assets and liabilities denominated in foreign currencies are translated at rates of exchange in effect at the date of the transaction. Expenses are translated at average rates for the period. Gains and losses arising on translation or settlement of foreign currency denominated transactions or balances are included in the determination of income.

Results of operations are translated into our company’s presentation currency, US dollars, at an appropriate average rate of exchange during the year. Net assets and liabilities are translated to US dollars for presentation purposes at rates of exchange in effect at the end of the period. Gains or losses arising on translation are recognized in other comprehensive income (loss) as foreign currency translation adjustments.

Recent Accounting Pronouncements

Our company has implemented all new accounting pronouncements that are in effect and that may impact our consolidated financial statements and we do not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our consolidated financial position or results of operations.

22
Table of Contents

Item 3. Quantitative and Qualitative Disclosure About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer), as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of quarter covered by this report. Based on the evaluation of these disclosure controls and procedures our chief executive officer (our principal executive officer) and our chief financial officer (principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective.

Changes in Internal Controls

During the quarter covered by this report there were no changes in our internal control over financial reporting that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

23
Table of Contents

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

We know of no material, existing or pending legal proceedings against us, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our company.

Item 1A. Risk Factors

As a “small reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

24
Table of Contents

Item 6. Exhibits

Exhibit
Number
Description

(3)
Articles of Incorporation and Bylaws
3.1
Articles of Incorporation 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.2
“Company Act” Memorandum of 649186 B.C. Ltd. Certificate of Amendment (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.3
Certificate of Filing of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.4
Certificate of Incorporation of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.5
Certificate of Name Change of 649186 B.C. Ltd. to Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.6
Transition Application of Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.7
Certificate of Name Change of Xerxes Health Corp. to Neurokine Pharmaceuticals Inc. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.8
Notice of Alteration to Authorized Share Structure (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.9
Notice of Alteration to Authorized Share Structure (incorporated by reference from our Current Report on Form 8-K filed on June 4, 2014)
3.10
Form 11 Notice of Alteration (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)
3.11
Articles (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)
3.12
Notice of Alteration changing name to Pivot Pharmaceuticals Inc. (incorporated by reference to our Current Report on Form 8-K filed on April 17, 2015)
3.13
Certificate of Name Change of Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc.
(10)
Material Contracts
10.1
Non-Exclusive License Agreement with Globe Laboratories Inc. dated June 17, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.2
Clinical Trial Services Agreement with Virtus Clinical Development (Pty) Limited dated March 1, 2009 (incorporated by reference to our Registration Statement on Form S-1/A filed on March 4, 2010)
10.3
Master Service Agreement with Northern Lipids Inc. dated October 2, 2007 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.4
Assignment of Invention (NK-001) dated January 30, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.5
Assignment of Invention (NK-002) dated April 18, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.6
Subscription Agreement with Ahmad Doroudian (incorporated by reference to our Form 8-K filed on August 12, 2010)
10.7
Debt Settlement Subscription Agreement dated September 26, 2013 with Ahmad Doroudian (incorporated by reference to our Quarterly Report on Form 10-Q filed on December 16, 2013)

25
Table of Contents

10.8
Director Services Agreement dated February 25, 2015 with Barbara-Jean Bormann-Kennedy (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.9
Director Services Agreement dated February 25, 2015 with Dr. Patrick Frankham (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.10
Director Services Agreement dated February 26, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.11
Consulting Services Agreement dated February 25, 2015 with Dr. Giora Davidai (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.12
Director Services Agreement dated November 19, 2015 with Dr. Patrick Frankham (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.13
Director Services Agreement dated November 19, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.14
Consulting Services Agreement dated November 19, 2015 with Dr. Giora Davidai (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.15
Plan of Merger and Acquisition Agreement between our company and IndUS Pharmaceuticals, Inc., dated November 4, 2015 (incorporated by reference to our Current Report on Form 8 K filed on November 23, 2015 and our Current Report on Form 8 K/A filed on February 3, 2016)
10.16
Employment Agreement dated November 20, 2015 with Dr. Pravin Chaturvedi (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.17
Employment Agreement dated February 1, 2016 with Dr. Ahmad Doroudian
10.18
Employment Agreement dated February 1, 2016 with Moira Ong
10.19
Consulting Services Agreement dated February 1, 2016 with Soho Capital Inc.
(31)
Rule 13a-14(d)/15d-14(d) Certifications
31.1*
Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer
31.2*
Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer
(32)
Section 1350 Certifications
32.1*
Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer
32.2*
Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer
99
Additional Exhibits
99.1
Audit Committee Charter
99.2
Stock Option Plan
101*
Interactive Data Files
101.INS
XBRL Instance Document
101.SCH
XBRL Taxonomy Extension Schema Document
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document

_________

* Filed herewith

26
Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PIVOT PHARMACEUTICALS INC.
(Registrant)

Dated: December 9, 2016
/s/ Pravin Chaturvedi
Dr. Pravin Chaturvedi
Chief Executive Officer and Director
(Principal Executive Officer)

Dated: December 9, 2016
/s/ Moira Ong
Moira Ong
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 pvotf_ex311.htm CERTIFICATION pvotf_ex311.htm

EXHIBIT 31.1

CERTIFICATION PURSUANT TO
18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Pravin Chaturvedi, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Pivot Pharmaceuticals Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 9, 2016
/s/ Pravin Chaturvedi
Pravin Chaturvedi
Chief Executive Officer and Director
(Principal Executive Officer)

EX-31.2 3 pvotf_ex312.htm CERTIFICATION pvotf_ex312.htm

EXHIBIT 31.2

CERTIFICATION PURSUANT TO
18 U.S.C. ss 1350, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Moira Ong, certify that:

Date: December 9, 2016
/s/ Moira Ong
Moira Ong
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 pvotf_ex321.htm CERTIFICATION pvotf_ex321.htm

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Pravin Chaturvedi, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) the Quarterly Report on Form 10-Q of Pivot Pharmaceuticals Inc. for the period ended October 31, 2016 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pivot Pharmaceuticals Inc.

Dated: December 9, 2016
/s/ Pravin Chaturvedi
Pravin Chaturvedi
Chief Executive Officer and Director
(Principal Executive Officer)
Pivot Pharmaceuticals Inc.

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to Pivot Pharmaceuticals Inc. and will be retained by Pivot Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 pvotf_ex322.htm CERTIFICATION pvotf_ex322.htm

EXHIBIT 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Moira Ong, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

Dated: December 9, 2016
/s/ Moira Ong
Moira Ong
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
Pivot Pharmaceuticals Inc.

EX-101.INS 6 pvotf-20161031.xml XBRL INSTANCE DOCUMENT 0001464165 2016-02-01 2016-10-31 0001464165 2016-12-09 0001464165 2016-01-31 0001464165 2015-02-01 2015-10-31 0001464165 2016-10-31 0001464165 2015-02-01 2016-01-31 0001464165 us-gaap:OfficeEquipmentMember 2016-10-31 0001464165 2015-08-01 2015-10-31 0001464165 2015-01-31 0001464165 pvotf:OptionsExpiringOnNovember302020Member 2016-02-01 2016-10-31 0001464165 pvotf:OptionsExpiringOnMay22021Member 2016-02-01 2016-10-31 0001464165 pvotf:OptionsExpiringOnFebruary222021Member 2016-02-01 2016-10-31 0001464165 pvotf:ExercisePriceOneMember 2016-10-31 0001464165 pvotf:ExercisePriceTwoMember 2016-10-31 0001464165 pvotf:ExercisePriceThreeMember 2016-10-31 0001464165 pvotf:ExercisePriceOneMember 2016-02-01 2016-10-31 0001464165 pvotf:ExercisePriceTwoMember 2016-02-01 2016-10-31 0001464165 pvotf:ExercisePriceThreeMember 2016-02-01 2016-10-31 0001464165 us-gaap:ChiefExecutiveOfficerMember 2016-10-31 0001464165 us-gaap:ChiefExecutiveOfficerMember 2016-01-31 0001464165 us-gaap:DirectorMember 2016-10-31 0001464165 us-gaap:DirectorMember 2016-01-31 0001464165 2016-08-01 2016-10-31 0001464165 pvotf:ExercisePriceFourMember 2016-10-31 0001464165 pvotf:ExercisePriceFourMember 2016-02-01 2016-10-31 0001464165 us-gaap:StockOptionMember 2016-10-31 0001464165 us-gaap:StockOptionMember 2016-01-31 0001464165 2015-10-31 0001464165 pvotf:PivotPharmaceuticalsInc.Member 2016-02-01 2016-10-31 0001464165 pvotf:IndUSPharmaceuticalsIncMember 2016-02-01 2016-10-31 0001464165 2016-09-30 0001464165 pvotf:ConvertibleLoanAgreementMember 2016-09-30 0001464165 pvotf:ConvertibleDebentureMember 2016-10-31 0001464165 pvotf:ConvertibleDebentureMember 2016-01-31 0001464165 pvotf:ConvertibleDebentureMember 2015-02-01 2016-01-31 0001464165 pvotf:ConvertibleDebentureMember 2016-02-01 2016-10-31 0001464165 us-gaap:WarrantMember 2016-02-01 2016-10-31 0001464165 us-gaap:WarrantMember 2016-01-31 0001464165 us-gaap:WarrantMember 2016-10-31 0001464165 us-gaap:OfficerMember 2015-04-01 2015-04-15 0001464165 2016-02-29 0001464165 2016-03-31 0001464165 2016-05-02 0001464165 2016-05-31 0001464165 2016-06-28 0001464165 2016-08-02 0001464165 2016-08-30 0001464165 2016-06-01 2016-06-30 0001464165 2016-02-01 2016-02-10 0001464165 2016-07-01 2016-07-31 0001464165 pvotf:ConvertibleLoanAgreementMember 2016-02-01 2016-10-31 0001464165 us-gaap:FairValueInputsLevel1Member 2016-10-31 0001464165 us-gaap:FairValueInputsLevel1Member 2016-01-31 0001464165 us-gaap:FairValueInputsLevel2Member 2016-10-31 0001464165 us-gaap:FairValueInputsLevel2Member 2016-01-31 0001464165 us-gaap:FairValueInputsLevel3Member 2016-10-31 0001464165 us-gaap:FairValueInputsLevel3Member 2016-01-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure Pivot Pharmaceuticals Inc. 0001464165 10-Q 2016-10-31 false --01-31 No No Yes Smaller Reporting Company 2017 75647100

74722100

75622100

25000

74722100

75622100

37622

25972

16721

866

4694

800

4557

37622

71639

206575

838

143639

1164614

8705847

1628

6200000

11479000

80000

200000

4000000

7250000

29000

4.00

3.93

2.96

3.11

0.0116

0.0045

0.0051

0.00

P4Y1M6D

P4Y6M

P4Y3M18D

P6M

P4M28D

9563500

100000

4000000

5437500

26000

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">As at October 31, 2016, the Company owed $4,694 (January 31, 2016 - $800) to a director of the Company, which is unsecured, non-interest bearing, and due on demand.</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">As at October 31, 2016, the Company owed $16,721 (January 31, 2016 Receivable of $866) to the Companys Chief Executive Officer.</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">As at October 31, 2016, the Company owed $4,557 (January 31, 2016 - $37,622) to related parties related to stock options to be granted pursuant to the Agreement and Plan of Merger and Acquisition Agreement dated as of November 4, 2015 between the Company and IndUS (Note 2).</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">On April 15, 2015, the Company issued 2,000,000 shares of common stock to an officer for services provided. This $191,356 of compensation expense has been included in professional fees.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"> </td> <td style="width: 4%; text-align: justify">(a)</td> <td style="text-align: justify">Basis of Presentation</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify">The consolidated financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in U.S. dollars. The Companys fiscal year-end is January 31.</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">(b)</td> <td style="text-align: justify">Use of Estimates</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">(c)</td> <td style="text-align: justify">Interim Financial Statements</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify">These interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Companys condensed consolidated financial position, results of operations and cash flows for the periods shown. The condensed consolidated results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Certain disclosures and financial information have been condensed in accordance with generally accepted accounting principles in the United States.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"> </td> <td style="width: 4%; text-align: justify">(d)</td> <td style="text-align: justify">Basis of Consolidation</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify">The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidating entities include:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="hdcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">% of ownership</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Jurisdiction</td> <td style="text-align: justify"> </td></tr> <tr> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify">Pivot Pharmaceuticals Inc.</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: center">Parent</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: center">Canada</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">IndUS Pharmaceuticals, Inc.</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; text-align: center">100%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">USA</td> <td style="text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"> </td> <td style="width: 4%; text-align: justify">(e)</td> <td style="text-align: justify">Loss Per Share</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify">The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method for all exercisable options and warrants and the if-converted method for all outstanding convertible debentures. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. At October 31, 2016 and 2015, the Company had 8,705,847 and zero potentially dilutive shares, respectively.</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="text-align: justify">(f)</td> <td style="text-align: justify">Financial Instruments and Fair Value Measures</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify">ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instruments categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:</td></tr> </table>   Level 1: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.   Level 2: Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.   Level 3: Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"> </td> <td style="width: 4%"> </td> <td style="text-align: justify">The Companys financial instruments consist principally of cash, amounts receivable, accounts payable and accrued liabilities, due to related parties and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on Level 1 inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"> </td> <td style="width: 4%; text-align: justify">(g)</td> <td style="text-align: justify">Recent Accounting Pronouncements</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td> </td> <td style="text-align: justify">The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt">Cost $</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Accumulated amortization $</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">October 31, 2016 Net carrying value $ (unaudited)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">January 31, 2016 Net carrying value $</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; width: 330px; text-align: justify">Office furniture and equipment</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">1,628</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">1,628</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">Depreciation expense included as a charge to income was $nil and $268 for the nine months ended October 31, 2016 and 2015, respectively.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt"> Cost $</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> Accumulated amortization $</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> October 31, 2016 Net carrying value $ (unaudited)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt"> January 31, 2016 Net carrying value $</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Office furniture and equipment</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">1,628</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">1,628</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify">(a)</td> <td style="text-align: justify">On February 10, 2016, the Company issued 100,000 shares of common stock to service providers for services provided valued at $68,000. The value of the common stock was based on the market price of the stock on the date of issuance.</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">(b)</td> <td style="text-align: justify">On February 29, 2016, March 31, 2016, May 2, 2016, May 31, 2016, June 28, 2016, August 2, 2016 and August 30, 2016, the Company issued 25,000 shares of common stock on each of these dates to the Companys CEO as monthly compensation valued at $15,000, $13,750, $7,500, $6,000, $4,875, $3,757 and $3,250, respectively. The value of the common stock was based on the market price of the stock on the date of issuance.</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">(c)</td> <td style="text-align: justify">In June 2016, 600,000 shares of common stock were issued to service providers and valued at $144,500 based on the market price of the stock on the dates of issuances.</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify">(d)</td> <td style="text-align: justify">On July 31, 2016, 25,000 shares of common stock, valued at $3,750, previously held in escrow were released to a member of the Companys Scientific Advisory Board (SAB member). The value of the common stock was based on the market price of the stock on the date of issuance. On October 31, 2016, common stock with a fair value of $1,697 remains issuable to this SAB member.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Effective December 30, 2015, the Company adopted a stock option plan. Under this plan, the Company may grant options to its directors, officers, employees and consultants up to an amount as determined by the Company and will be no more than a percentage of its outstanding common stock as may be required by the stock exchange the Company is listed with. The exercise price of the stock options will be determined by the Company and will be no less than any minimum exercise price as may be required by the stock exchange the Company is listed with.</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The following table summarizes the continuity of the Companys stock options:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center">Number of Options</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price (US$)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Aggregate Intrinsic Value (US$)</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, January 31, 2015 </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">80,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0.05</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">6,200,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4.1</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4,930,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(80,000</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(0.05</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, January 31, 2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">6,200,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4.1</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4,930,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">7,279,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.70</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4.3</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Forfeited</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(2,000,000</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(0.10</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, October 31, 2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">11,479,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">0.48</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">4.2</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">36,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">The fair value of stock-based compensation expense was estimated using the Black-Scholes option pricing model and the following assumptions:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expected Volatility</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Risk-free Interest Rate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expected Dividend Yield</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expected Life (in years)</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">200,000 options expiring on November 30, 2020</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">400</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">1.16</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">4.1</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">7,250,000 options expiring on February 22, 2021</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">393</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">1.16</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4.3</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">29,000 options expiring on May 2, 2021</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">393</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">1.16</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">4.5</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">Additional information regarding stock options as of October 31, 2016, is as follows:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td colspan="2" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Options Outstanding</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Option Exercisable</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt">Exercise Price $</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expiry Date</td> <td style="text-align: justify"> </td></tr> <tr> <td colspan="2" style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="width: 21%; text-align: right">200,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 21%; text-align: right">100,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 14%; text-align: center">0.25</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="width: 35%; text-align: center">November 30, 2020</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: right">4,000,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4,000,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">December 14, 2020</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: right">7,250,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">5,437,500</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0.70</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">February 22, 2021</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; text-align: right">29,000</td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">26,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0.34</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">May 2, 2021</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">11,479,000</td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">9,563,500</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">$83,068 of stock-based compensation have yet to be recognized and will be recognized in future periods.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid; text-align: center">Number of Options</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Exercise Price (US$)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid; text-align: center">Weighted Average Remaining Contractual Life (years)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Aggregate Intrinsic Value (US$)</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, January 31, 2015 </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">80,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0.05</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">6,200,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4.1</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4,930,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Expired</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(80,000</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(0.05</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, January 31, 2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">6,200,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4.1</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4,930,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">7,279,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">0.70</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4.3</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Forfeited</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(2,000,000</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">(0.10</td> <td style="vertical-align: bottom; text-align: justify">)</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Outstanding, October 31, 2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">11,479,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">0.48</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">4.2</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">36,000</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">Options Outstanding</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td colspan="2" id="hdcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Option Exercisable</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt">Exercise Price $</td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expiry Date</td> <td style="text-align: justify"> </td></tr> <tr> <td colspan="2" style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="width: 21%; text-align: right">200,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 21%; text-align: right">100,000</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 14%; text-align: center">0.25</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="width: 35%; text-align: center">November 30, 2020</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: right">4,000,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">4,000,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">December 14, 2020</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: right">7,250,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right">5,437,500</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0.70</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">February 22, 2021</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; text-align: right">29,000</td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">26,000</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0.34</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">May 2, 2021</td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; text-align: right">11,479,000</td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">9,563,500</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="text-align: justify"> </td></tr> </table>

31576

19211

71639

206575

103215

225786

2900

106115

228686

447115

142588

397482

774725

435104

1390400

7054499

7324881

16206 1697

6174601

10661752

745251

635654

-14319546

-19785698

-328989

-1161714

106115

228686

-5201514

-3530047

-7842

-690304

5201514

3530047

7842

690304

100421

355727

128058

9938

3917354

2298813

-116405

548407

1045722

866505

-8264

71301

-138017

-8733

-4367

-60658

269

-212354 14958 -212354

-264638

14958

-264638

-5466152

-3515089

-7842

-954942

75212555

76886477

85570289

75613498

-0.07

-0.05

-0.01

-5356555

-3776388

134605

-995511

109597

-261299

142447

-40569

256382 3310773

366124

71000

-5938

15812

-276328

-163818

16500

1075

240000

381350

397850

241075

13414

65544

134936

142801

284184

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">On September 30, 2016, the Company issued a convertible debenture with a non-related party for $500,000 Canadian Dollars ($380,411 US Dollars at September 30, 2016) (Initial Advance). The debenture is secured under a General Security Agreement, bears interest at 8% per annum and matures on the earlier of:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td style="width: 4%; text-align: justify"> </td> <td style="vertical-align: top; width: 4%; font: 12pt Times New Roman, Times, Serif; text-align: justify">·</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: justify">The date the lender demands repayment of principal and interest following an event of default,</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: justify">·</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: justify">The date of a dissolution event,</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: justify">·</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: justify">The date of a liquidity event, and</td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: justify">·</td> <td style="vertical-align: top; font: 12pt Times New Roman, Times, Serif; text-align: justify">March 30, 2017.</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The Company may request one or more additional advances of up to an aggregate amount of $1,000,000 Canadian Dollars (Additional Advances) provided that the aggregate amount under the convertible debenture does not exceed $1,500,000 Canadian Dollars.</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The note, including the Initial Advance and any Additional Advances, is convertible into common shares at a conversion price equal to the average closing market price of the Companys common stock during the five day period leading up to the conversion date. The Company recorded the conversion feature of the convertible debenture as a derivative liability at an estimated fair value of $221,158 with a corresponding discount to the convertible debenture (Note 5).</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td style="text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Pursuant to the convertible loan agreement, the Company issued 434,622 share purchase warrants to which the lender may acquire an interest in the Company equal to 12% of the maximum principal amount outstanding at any time at a price of $0.10, which equates to the ten day average trading price of the Companys common stock determined as at September 30, 2016. The Company calculated the 434,622 share purchase warrants based on the maximum outstanding principal balance on the convertible loan as of September 30, 2016. The Company recorded the share purchase warrant at an estimated fair value of $20,154 with a corresponding discount to the convertible debenture (Note 8).</td></tr> </table>    <table cellspacing="0" cellpadding="0" style="width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">As of October 31, 2016, the carrying value of the convertible debenture is $191,215 Canadian Dollars ($142,588 US Dollars at October 31, 2016) (January 31, 2016 - $nil) with accrued interest $2,533 (January 31, 2016 - $nil). As of October 31, 2016, the fair value of the conversion option derivative liability is $447,115 (January 31, 2016 - $nil).</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">Derivative liability consists of convertible debenture with variable conversion price (Note 4). The fair value of derivative liability as at October 31, 2016 and January 31, 2016 is as follows:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid"> October 31, 2016 $</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> January 31, 2016 $</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">September 2016 convertible debenture</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">447,115</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right">447,115</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1.5pt double; text-align: justify"> </td> <td style="border-bottom: black 1.5pt double; vertical-align: bottom; text-align: right"></td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">The fair value of derivative financial liability was determined using the Black-Scholes option pricing model, using the following assumptions:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expected Volatility</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Risk-free Interest Rate</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expected Dividend Yield</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expected Life (in years)</td> <td style="text-align: justify"> </td></tr> <tr> <td style="vertical-align: top; text-align: justify">As at issuance date:</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">September 2016 convertible debenture</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">296</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0.45</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0</td> <td style="vertical-align: bottom; width: 1%; text-align: justify">%</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right">0.50</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">As at October 31, 2016:</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">September 2016 convertible debenture</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">311</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0.51</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0</td> <td style="vertical-align: bottom; text-align: justify">%</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0.41</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The following table summarizes the continuity of share purchase warrant:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid">Number of Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid">Weighted Average Exercise Price $</td> <td style="text-align: center"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, January 31, 2016</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">434,622</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, October 31, 2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">434,622</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">As at October 31, 2016, the following share purchase warrant was outstanding:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td colspan="2" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Number of Warrants </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt">Exercise Price $</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expiry Date</td> <td style="text-align: justify"> </td></tr> <tr> <td colspan="2" style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: right">434,622</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">March 30, 2017</td> <td style="text-align: justify"> </td></tr> <tr> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td> <td> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">Pursuant to the convertible debenture (Note 4), the Company will be required to issue additional share purchase warrants on any Additional Advances to which the lender may acquire an interest in the Company equal to 12% of the maximum principal amount outstanding.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The consolidated financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in U.S. dollars. The Companys fiscal year-end is January 31.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">These interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Companys condensed consolidated financial position, results of operations and cash flows for the periods shown. The condensed consolidated results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Certain disclosures and financial information have been condensed in accordance with generally accepted accounting principles in the United States.</td></tr> </table> <table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidating entities include:</td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="hdcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">% of ownership</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Jurisdiction</td> <td style="text-align: justify"> </td></tr> <tr> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify">Pivot Pharmaceuticals Inc.</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: center">Parent</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: center">Canada</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">IndUS Pharmaceuticals, Inc.</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; text-align: center">100%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">USA</td> <td style="text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method for all exercisable options and warrants and the if-converted method for all outstanding convertible debentures. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. At October 31, 2016 and 2015, the Company had 8,705,847 and zero potentially dilutive shares, respectively.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instruments categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:</td></tr> </table>   Level 1: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.   Level 2: Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.   Level 3: Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.   <table cellspacing="0" cellpadding="0" style="width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%; font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="width: 4%"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The Companys financial instruments consist principally of cash, amounts receivable, accounts payable and accrued liabilities, due to related parties and convertible debenture. Pursuant to ASC 820, the fair value of our cash is determined based on Level 1 inputs, which consist of quoted prices in active markets for identical assets. The recorded values of all other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="hdcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">% of ownership</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Jurisdiction</td> <td style="text-align: justify"> </td></tr> <tr> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: center"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; text-align: justify">Pivot Pharmaceuticals Inc.</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: center">Parent</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: center">Canada</td> <td style="width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">IndUS Pharmaceuticals, Inc.</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; text-align: center">100%</td> <td style="vertical-align: bottom"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="text-align: center">USA</td> <td style="text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom: black 1pt solid"> Number of Warrants</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1pt solid"> Weighted Average Exercise Price $</td> <td style="text-align: center"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td colspan="2" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Balance, January 31, 2016</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 9%; text-align: right"></td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; padding-left: 8.05pt; text-align: justify">Granted</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">434,622</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> <tr style="background-color: white"> <td style="vertical-align: top; text-align: justify">Balance, October 31, 2016</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">434,622</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom: black 1pt solid; text-align: justify"> </td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; text-align: right">0.10</td> <td style="vertical-align: bottom; text-align: justify"> </td></tr> </table>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%"> <tr> <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1pt solid; text-align: center">Number of Warrants </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="hdcell" style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt"> Exercise Price $</td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Expiry Date</td> <td style="text-align: justify"> </td></tr> <tr> <td colspan="2" style="text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td id="ffcell" style="vertical-align: bottom; text-align: right"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: justify"> </td> <td style="vertical-align: bottom; text-align: right"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="width: 26%; text-align: right">434,622</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 26%; text-align: center">0.10</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="width: 42%; text-align: center">March 30, 2017</td> <td style="width: 1%; text-align: justify"> </td></tr> </table>

48672

3612

1.00

Canada

USA

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The Companys financial liabilities carried at fair value measured on a recurring basis as of October 31, 2016 and January 31, 2016, consisted of the following:</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Total fair value at October 31, 2016</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Quoted prices in active markets (Level 1)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant other observable inputs (Level 2)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant unobservable inputs (Level 3)</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Derivative liability (1)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">447,115</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">447,115</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Total fair value at January 31, 2016</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Quoted prices in active markets (Level 1)</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant other observable inputs (Level 2)</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant unobservable inputs (Level 3)</td> <td style="text-align: center"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Derivative liability (1)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: top"> <td style="width: 4%"> </td> <td style="text-align: justify">(1) Derivative liability amounts are due to the embedded derivatives of convertible debenture issued by the Company and are calculated using the Black Scholes pricing model (Note 5).</td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify">The Company has no financial assets carried at fair value.</td></tr> </table>

<table cellspacing="0" cellpadding="0" style="width: 100%"> <tr style="vertical-align: top"> <td> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify">The Companys financial liabilities carried at fair value measured on a recurring basis as of October 31, 2016 and January 31, 2016, consisted of the following:</td></tr> <tr> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" id="hdcell" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Total fair value at October 31, 2016</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Quoted prices in active markets (Level 1)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant other observable inputs (Level 2)</td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant unobservable inputs (Level 3)</td> <td style="text-align: justify"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Derivative liability (1)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td id="ffcell" style="vertical-align: bottom; width: 9%; text-align: right">447,115</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">447,115</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify">$</td> <td style="vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> </table>   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; font-size-adjust: none; font-stretch: normal"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt; text-align: center">Total fair value at January 31, 2016</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Quoted prices in active markets (Level 1)</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant other observable inputs (Level 2)</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom-style: solid; border-bottom-width: 1pt">Significant unobservable inputs (Level 3)</td> <td style="text-align: center"> </td></tr> <tr> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top; text-align: justify">Derivative liability (1)</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td> <td style="vertical-align: bottom; width: 1%; border-bottom: black 1pt solid; text-align: justify">$</td> <td style="border-bottom: black 1pt solid; vertical-align: bottom; width: 9%; text-align: right">-</td> <td style="vertical-align: bottom; width: 1%; text-align: justify"> </td></tr> </table>

142588

380411

0.08

221158

2533

7279000

6200000

434622

80000

2000000

0.10

0.48

0.05

0.70

0.10

-0.05

-0.10

4930000

36000

P4Y3M18D P4Y1M6D P4Y2M12D P4Y1M6D

0.25

0.10

0.70

0.34

2020-11-30

2020-12-14

2021-02-22

2021-05-02

March 30, 2017

0.10

2015-11-04

191356

15000

13750

7500

6000

4875

3757

3250

600000

100000

2000000

144500

68000

25000

3750

434622

0.10

0.12

20154

434622

0.10

-4300354

83068

447115

Parent

EX-101.SCH 7 pvotf-20161031.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Disclosure - Nature of Operations and Continuance of Business link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Property and Equipment link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Convertible Debenture link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - Derivative Liability link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Stock Options link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Share Purchase Warrant link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Property and Equipment (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Derivative Liability (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Stock Options (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Share Purchase Warrant (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Nature of Operations and Continuance of Business (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Property and Equipment (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Property and Equipment (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Convertible Debenture (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Derivative Liability (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Derivative Liability (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Common Stock (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Stock Options (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Stock Options (Details 2) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Stock Options (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - Share Purchase Warrant (Details) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - Share Purchase Warrant (Details 1) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - Related Party Transactions (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 pvotf-20161031_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 pvotf-20161031_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 pvotf-20161031_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Common Stock Equity Components [Axis] Common Stock Issuable Additional Paid-In Capital Deficit Office furniture and equipment [Member] Property, Plant and Equipment, Type [Axis] On December 17, 2010 [Member] Debt Instrument [Axis] On February 23, 2011 [Member] On July 4, 2011 [Member] On April 26, 2013 [Member] On June 27, 2014 [Member] On December 11, 2014 [Member] December 2010 convertible debenture Derivative Instrument [Axis] February 2011 convertible debenture Default Penalty On Convertible Debentures 380,000 Warrants Expiring on July 30, 2015 As at issuance date- December 2010 convertible debenture As At Issuance Date February 2011 Convertible Debenture As at issuance date- default penalty on covertible debenture As at issuance date 380,000 Warrants Expiring on July 30, 2015 As at January 31, 2015 - December 2010 convertible debenture As at January 31, 2015 - February 2011 convertible debenture As at January 31, 2015 - Default penalty on covertible debenture As at January 31, 2015 - 380,000 warrants expiring on July 30, 2015 On April 27, 2014 [Member] Report Date [Axis] On September 19, 2014 [Member] On March 24, 2013 [Member] On September 24, 2013 [Member] Officer [Member] Related Party Transaction [Axis] Director [Member] 2029 [Member] 2030 [Member] 2031 [Member] 2032 [Member] 2033 [Member] 2034 [Member] 2035 [Member] Warrant [Member] Stock Option [Member] Award Type [Axis] Maximum [Member] Range [Axis] Minimum [Member] 200,000 options expiring on November 30, 2020 [Member] 29,000 options expiring on May 2, 2021 [Member] 7,250,000 options expiring on February 22, 2021 [Member] Exercise Price 0.25 [Member] Exercise Price 0.10 [Member] Exercise Price 0.70 [Member] CEO [Member] Exercise Price 0.34 [Member] Pivot Pharmaceuticals Inc. [Member] Consolidation Items [Axis] IndUS Pharmaceuticals, Inc. [Member] Convertible Loan Agreement [Member] Debt Conversion Description [Axis] September 2016 Convertible Debenture [Member] Liability Class [Axis] Quoted prices in active markets (Level 1) [Member] Fair Value, Hierarchy [Axis] Significant other observable inputs (Level 2) [Member] Significant unobservable inputs (Level 3) [Member] Document And Entity Information Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Is Entity a Well-known Seasoned Issuer? Is Entity a Voluntary Filer? Is Entity's Reporting Status Current? Entity Filer Category Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] Assets Current assets: Cash Prepaids and other current assets Total current assets Security deposit Total assets Liabilities and Stockholders' Deficit Current liabilities Accounts payable and accrued liabilities Due to related parties (Note 9) Convertible debenture, net of discount (Note 4) Derivative liability (Note 5) Total liabilities Stockholders' Deficit Common stock: Unlimited shares authorized, without par value, 75,622,100 and 74,722,100 shares issued and outstanding, respectively Common stock issuable (Note 6) Additional paid-in capital Accumulated other comprehensive income Accumulated deficit Total stockholder's deficit Total liabilities and stockholder's deficit Condensed Consolidated Balance Sheets Parenthetical Common stock, Shares issued Common stock, Shares outstanding Condensed Consolidated Statements Of Operations Revenue Expenses Depreciation and amortization Foreign exchange loss General and administrative Management fees (Note 9) Professional fees Total expenses Loss from operations Other income (expense) Amortization of discount on convertible debenture Interest expense (Loss) gain on change in fair value of derivative liabilities Total other income (expense) Net loss Other comprehensive income (loss) Foreign currency translation adjustment Net comprehensive income (loss) Net loss per share, basic and diluted Weighted average shares outstanding - basic and diluted Condensed Consolidated Statements Of Cash Flows Operating activities Net loss Adjustments to reconcile net loss to net cash used in operating activities: Amortization of discount on convertible debenture Depreciation Fair value of stock options vested Loss (gain) on change in fair value of derivative liabilities Stock issued for services Changes in operating assets and liabilities: Prepaids and other current assets Accounts payable and accrued liabilities Net cash used in operating activities Financing activities Proceeds from convertible debenture Proceeds from stock to be issued Proceeds from related party advances Net cash provided by financing activities Effects of exchange rate changes on cash Increase in cash Cash - beginning of period Cash - end of period Non-cash investing and financing activities Debt discounts on convertible debt Supplemental disclosures: Interest paid Income tax paid Notes to Financial Statements Note 1. Nature of Operations and Continuance of Business Note 2. Significant Accounting Policies Note 3. Property and Equipment Note 4. Convertible Debenture Note 5. Derivative Liability Note 6. Common Stock Note 7. Stock Options Note 8. Share Purchase Warrant Note 9. Related Party Transactions Note 10. Fair Value Measurements Note 11. Subsequent Events Significant Accounting Policies Policies Basis of Presentation Use of Estimates Interim Financial Statements Basis of Consolidation Loss Per Share Financial Instruments and Fair Value Measures Recent Accounting Pronouncements Significant Accounting Policies Tables Basis of Consolidation Property And Equipment Tables Property and Equipment Derivative Liability Tables Schedule of Fair value of derivative liability Schedule of Interest Rate Derivatives Stock Options Tables Schedule of Stock Options Fair value of stock-based compensation expense Additional information of stock options Share Purchase Warrant Tables Schedule of continuity of share purchase warrants Schedule of share purchase warrant was outstanding Fair Value Measurements Tables Fair Value Measurement Nature Of Operations And Continuance Of Business Details Narrative Working capital deficit EX-101.PRE 11 pvotf-20161031_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Oct. 31, 2016	Dec. 09, 2016
Document And Entity Information
Entity Registrant Name	Pivot Pharmaceuticals Inc.
Entity Central Index Key	0001464165
Document Type	10-Q
Document Period End Date	Oct. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--01-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		75,647,100
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2017

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Oct. 31, 2016	Jan. 31, 2016
Current assets:
Cash	$ 206,575	$ 71,639
Prepaids and other current assets	19,211	31,576
Total current assets	225,786	103,215
Security deposit	2,900	2,900
Total assets	228,686	106,115
Current liabilities
Accounts payable and accrued liabilities	774,725	397,482
Due to related parties (Note 9)	25,972	37,622
Convertible debenture, net of discount (Note 4)	142,588
Derivative liability (Note 5)	447,115
Total liabilities	1,390,400	435,104
Stockholders' Deficit
Common stock: Unlimited shares authorized, without par value, 75,622,100 and 74,722,100 shares issued and outstanding, respectively	7,324,881	7,054,499
Common stock issuable (Note 6)	1,697	16,206
Additional paid-in capital	10,661,752	6,174,601
Accumulated other comprehensive income	635,654	745,251
Accumulated deficit	(19,785,698)	(14,319,546)
Total stockholder's deficit	(1,161,714)	(328,989)
Total liabilities and stockholder's deficit	$ 228,686	$ 106,115

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - shares	Oct. 31, 2016	Jan. 31, 2016
Condensed Consolidated Balance Sheets Parenthetical
Common stock, Shares issued	75,622,100	74,722,100
Common stock, Shares outstanding	75,622,100	74,722,100

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2016	Oct. 31, 2015
Condensed Consolidated Statements Of Operations
Revenue
Expenses
Depreciation and amortization		86		269
Foreign exchange loss	60,658	4,367	138,017	8,733
General and administrative	71,301	(8,264)	1,045,722	866,505
Management fees (Note 9)	548,407	(116,405)	3,917,354	2,298,813
Professional fees	9,938	128,058	100,421	355,727
Total expenses	690,304	7,842	5,201,514	3,530,047
Loss from operations	(690,304)	(7,842)	(5,201,514)	(3,530,047)
Other income (expense)
Amortization of discount on convertible debenture	(48,672)		(48,672)
Interest expense	(3,612)		(3,612)
(Loss) gain on change in fair value of derivative liabilities	(212,354)		(212,354)	14,958
Total other income (expense)	(264,638)		(264,638)	14,958
Net loss	(954,942)	(7,842)	(5,466,152)	(3,515,089)
Other comprehensive income (loss)
Foreign currency translation adjustment	(40,569)	142,447	109,597	(261,299)
Net comprehensive income (loss)	$ (995,511)	$ 134,605	$ (5,356,555)	$ (3,776,388)
Net loss per share, basic and diluted	$ (0.01)	$ 0	$ (0.07)	$ (0.05)
Weighted average shares outstanding - basic and diluted	75,613,498	85,570,289	75,212,555	76,886,477

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2016	Oct. 31, 2015
Operating activities
Net loss	$ (954,942)	$ (7,842)	$ (5,466,152)	$ (3,515,089)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of discount on convertible debenture	48,672		48,672
Depreciation		86		269
Fair value of stock options vested			4,300,354
Loss (gain) on change in fair value of derivative liabilities	212,354		212,354	(14,958)
Stock issued for services			256,382	3,310,773
Changes in operating assets and liabilities:
Prepaids and other current assets			5,938	(15,812)
Accounts payable and accrued liabilities			366,124	71,000
Net cash used in operating activities			(276,328)	(163,818)
Financing activities
Proceeds from convertible debenture			381,350
Proceeds from stock to be issued				240,000
Proceeds from related party advances			16,500	1,075
Net cash provided by financing activities			397,850	241,075
Effects of exchange rate changes on cash			13,414	65,544
Increase in cash			134,936	142,801
Cash - beginning of period			71,639	838
Cash - end of period	$ 206,575	$ 143,639	206,575	143,639
Non-cash investing and financing activities
Debt discounts on convertible debt			284,184
Supplemental disclosures:
Interest paid
Income tax paid

XML 17 R6.htm IDEA: XBRL DOCUMENT

Nature of Operations and Continuance of Business

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 1. Nature of Operations and Continuance of Business

Pivot Pharmaceuticals Inc. (the “Company”) was incorporated in British Columbia under the Business Corporations Act on June 10, 2002. On April 7, 2015, the Company changed its name from Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc. The Company is in the business of developing and commercializing therapeutic pharmaceutical products, focused on the strategy of identifying new therapeutic treatments to address unmet medical needs in women’s health.

These consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. As of October 31, 2016, the Company has not earned any revenue, has a working capital deficit of $1,164,614 and an accumulated deficit of $19,785,698. The continued operations of the Company are dependent on its ability to generate future cash flows or obtain additional financing. These factors raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recorded assets or liabilities that might be necessary should the Company be unable to continue as a going concern.

XML 18 R7.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 2. Significant Accounting Policies

	(a)	Basis of Presentation

		The consolidated financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in U.S. dollars. The Company’s fiscal year-end is January 31.

	(b)	Use of Estimates

		The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

	(c)	Interim Financial Statements

		These interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial position, results of operations and cash flows for the periods shown. The condensed consolidated results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Certain disclosures and financial information have been condensed in accordance with generally accepted accounting principles in the United States.

	(d)	Basis of Consolidation

		The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidating entities include:

	(e)	Loss Per Share

		The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method for all exercisable options and warrants and the if-converted method for all outstanding convertible debentures. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. At October 31, 2016 and 2015, the Company had 8,705,847 and zero potentially dilutive shares, respectively.

	(f)	Financial Instruments and Fair Value Measures

		ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

	(g)	Recent Accounting Pronouncements

		The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.

XML 19 R8.htm IDEA: XBRL DOCUMENT

Property and Equipment

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 3. Property and Equipment

Cost

Accumulated amortization

October 31,

2016

Net carrying
value

(unaudited)

January 31,

2016

Net carrying

value

Office furniture and equipment

1,628

–

Depreciation expense included as a charge to income was $nil and $268 for the nine months ended October 31, 2016 and 2015, respectively.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Convertible Debenture

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 4. Convertible Debenture

On September 30, 2016, the Company issued a convertible debenture with a non-related party for $500,000 Canadian Dollars ($380,411 US Dollars at September 30, 2016) (“Initial Advance”). The debenture is secured under a General Security Agreement, bears interest at 8% per annum and matures on the earlier of:

	·	The date the lender demands repayment of principal and interest following an event of default,
	·	The date of a dissolution event,
	·	The date of a liquidity event, and
	·	March 30, 2017.

	The Company may request one or more additional advances of up to an aggregate amount of $1,000,000 Canadian Dollars (“Additional Advances”) provided that the aggregate amount under the convertible debenture does not exceed $1,500,000 Canadian Dollars.

	The note, including the Initial Advance and any Additional Advances, is convertible into common shares at a conversion price equal to the average closing market price of the Company’s common stock during the five day period leading up to the conversion date. The Company recorded the conversion feature of the convertible debenture as a derivative liability at an estimated fair value of $221,158 with a corresponding discount to the convertible debenture (Note 5).

	Pursuant to the convertible loan agreement, the Company issued 434,622 share purchase warrants to which the lender may acquire an interest in the Company equal to 12% of the maximum principal amount outstanding at any time at a price of $0.10, which equates to the ten day average trading price of the Company’s common stock determined as at September 30, 2016. The Company calculated the 434,622 share purchase warrants based on the maximum outstanding principal balance on the convertible loan as of September 30, 2016. The Company recorded the share purchase warrant at an estimated fair value of $20,154 with a corresponding discount to the convertible debenture (Note 8).

As of October 31, 2016, the carrying value of the convertible debenture is $191,215 Canadian Dollars ($142,588 US Dollars at October 31, 2016) (January 31, 2016 - $nil) with accrued interest $2,533 (January 31, 2016 - $nil). As of October 31, 2016, the fair value of the conversion option derivative liability is $447,115 (January 31, 2016 - $nil).

XML 21 R10.htm IDEA: XBRL DOCUMENT

Derivative Liability

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 5. Derivative Liability

Derivative liability consists of convertible debenture with variable conversion price (Note 4). The fair value of derivative liability as at October 31, 2016 and January 31, 2016 is as follows:

	October 31, 2016 $		January 31, 2016 $

September 2016 convertible debenture		447,115		–

		447,115		–

The fair value of derivative financial liability was determined using the Black-Scholes option pricing model, using the following assumptions:

	Expected Volatility			Risk-free Interest Rate			Expected Dividend Yield			Expected Life (in years)
As at issuance date:
September 2016 convertible debenture		296	%		0.45	%		0	%		0.50
As at October 31, 2016:
September 2016 convertible debenture		311	%		0.51	%		0	%		0.41

XML 22 R11.htm IDEA: XBRL DOCUMENT

Common Stock

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 6. Common Stock

(a)	On February 10, 2016, the Company issued 100,000 shares of common stock to service providers for services provided valued at $68,000. The value of the common stock was based on the market price of the stock on the date of issuance.

(b)	On February 29, 2016, March 31, 2016, May 2, 2016, May 31, 2016, June 28, 2016, August 2, 2016 and August 30, 2016, the Company issued 25,000 shares of common stock on each of these dates to the Company’s CEO as monthly compensation valued at $15,000, $13,750, $7,500, $6,000, $4,875, $3,757 and $3,250, respectively. The value of the common stock was based on the market price of the stock on the date of issuance.

(c)	In June 2016, 600,000 shares of common stock were issued to service providers and valued at $144,500 based on the market price of the stock on the dates of issuances.

(d)	On July 31, 2016, 25,000 shares of common stock, valued at $3,750, previously held in escrow were released to a member of the Company’s Scientific Advisory Board (“SAB member”). The value of the common stock was based on the market price of the stock on the date of issuance. On October 31, 2016, common stock with a fair value of $1,697 remains issuable to this SAB member.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Stock Options

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 7. Stock Options

	Effective December 30, 2015, the Company adopted a stock option plan. Under this plan, the Company may grant options to its directors, officers, employees and consultants up to an amount as determined by the Company and will be no more than a percentage of its outstanding common stock as may be required by the stock exchange the Company is listed with. The exercise price of the stock options will be determined by the Company and will be no less than any minimum exercise price as may be required by the stock exchange the Company is listed with.

	The following table summarizes the continuity of the Company’s stock options:

	Number of Options			Weighted Average Exercise Price (US$)			Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value (US$)

Outstanding, January 31, 2015		80,000			0.05			–		–
Granted		6,200,000			0.10			4.1		4,930,000
Expired		(80,000	)		(0.05	)		–		–

Outstanding, January 31, 2016		6,200,000			0.10			4.1		4,930,000
Granted		7,279,000			0.70			4.3		–
Forfeited		(2,000,000	)		(0.10	)		–		–

Outstanding, October 31, 2016		11,479,000			0.48			4.2		36,000

The fair value of stock-based compensation expense was estimated using the Black-Scholes option pricing model and the following assumptions:

	Expected Volatility			Risk-free Interest Rate			Expected Dividend Yield			Expected Life (in years)
200,000 options expiring on November 30, 2020		400	%		1.16	%		0	%		4.1
7,250,000 options expiring on February 22, 2021		393	%		1.16	%		0	%		4.3
29,000 options expiring on May 2, 2021		393	%		1.16	%		0	%		4.5

Additional information regarding stock options as of October 31, 2016, is as follows:

Options Outstanding		Option Exercisable		Exercise Price $	Expiry Date

	200,000		100,000	0.25	November 30, 2020
	4,000,000		4,000,000	0.10	December 14, 2020
	7,250,000		5,437,500	0.70	February 22, 2021
	29,000		26,000	0.34	May 2, 2021
	11,479,000		9,563,500

$83,068 of stock-based compensation have yet to be recognized and will be recognized in future periods.

- Definition

The entire disclosure for a company's election to apply the fair value option for measurement and reporting of eligible financial assets and liabilities (as defined), as well as certain other eligible items (as defined) included in the statement of financial position, whether such option is elected for a single eligible item or a group of similar eligible items and is in addition to other disclosures concerning fair value which the company may be required to provide. Such disclosure might be expected to include: (1) for items included in the statement of financial position: (a) the reasons for electing a fair value option for each eligible item or group of similar eligible items; (b) if the fair value option is elected for some but not all eligible items within a group of similar eligible items: (i) a description of those similar items and the reasons for partial election and (ii) information of how the group of similar items relates to individual balance sheet line items; (c) for each line item in the statement of financial position that includes an item or items for which the fair value option has been elected: (i) information of how each line item in the statement of financial position relates to major categories of assets and liabilities presented in accordance with other fair value disclosures and (ii) the aggregate carrying amount of ineligible items included in each line item in the balance sheet, if any; (d) the difference between the aggregate fair value and the aggregate unpaid principal balance (assuming contractual principal amounts and fair value option elected) of: (i) loans and long-term receivables (other than securities otherwise reported at fair value) and (ii) long-term debt instruments; (e) for loans held as assets for which the fair value option has been elected: (i) the aggregate fair value of loans that are 90 days or more past due, (ii) if the policy is to recognize interest income separately from other changes in fair value, the aggregate fair value of loans in nonaccrual status, and (iii) the difference between the aggregate fair value and the aggregate unpaid principal balance for loans that are 90 days or more past due, in nonaccrual status, or both; (f) for investments that would have been accounted for under the equity method if the entity had not chosen to apply the fair value option, the information required for such investments, if material either individually or in the aggregate; (2) for items included in the income statement: (a) the amounts of gains and losses from fair value changes included in earnings and in which line in the income statement those gains and losses are reported whether or not combined with gains and losses from items required to be accounted for at fair value; (b) a description of how interest and dividends are measured and where they are reported in the income statement; (c) for loans and other receivables held as assets: (i) the estimated amount of gains or losses included in earnings attributable to changes in instrument-specific credit risk and (ii) how the gains or losses attributable to changes in instrument-specific credit risk were determined; (d) for liabilities with fair values that have been significantly affected during the reporting period by changes in the instrument-specific credit risk: (i) the estimated amount of gains and losses from fair value changes included in earnings that are attributable to changes in the instrument-specific credit risk, (ii) qualitative information about the reasons for those changes, and (iii) how the gains and losses attributable to changes in instrument-specific credit risk were determined; and (3) certain other disclosures as required or determined to be provided.

+ References + Details

XML 24 R13.htm IDEA: XBRL DOCUMENT

Share Purchase Warrant

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 8. Share Purchase Warrant

The following table summarizes the continuity of share purchase warrant:

	Number of Warrants		Weighted Average Exercise Price $

Balance, January 31, 2016		–		–

Granted		434,622		0.10
Balance, October 31, 2016		434,622		0.10

As at October 31, 2016, the following share purchase warrant was outstanding:

Number of Warrants		Exercise Price $	Expiry Date

	434,622	0.10	March 30, 2017

XML 25 R14.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 9. Related Party Transactions

As at October 31, 2016, the Company owed $4,694 (January 31, 2016 - $800) to a director of the Company, which is unsecured, non-interest bearing, and due on demand.

As at October 31, 2016, the Company owed $16,721 (January 31, 2016 – Receivable of $866) to the Company’s Chief Executive Officer.

As at October 31, 2016, the Company owed $4,557 (January 31, 2016 - $37,622) to related parties related to stock options to be granted pursuant to the Agreement and Plan of Merger and Acquisition Agreement dated as of November 4, 2015 between the Company and IndUS (Note 2).

On April 15, 2015, the Company issued 2,000,000 shares of common stock to an officer for services provided. This $191,356 of compensation expense has been included in professional fees.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Fair Value Measurements

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 10. Fair Value Measurements

	The Company’s financial liabilities carried at fair value measured on a recurring basis as of October 31, 2016 and January 31, 2016, consisted of the following:

Total fair
value at
October 31,
2016

Quoted
prices in
active markets

(Level 1)

Significant
other
observable
inputs

(Level 2)

Significant unobservable
inputs

(Level 3)

Derivative liability ⁽¹⁾

447,115

Total fair
value at
January 31,
2016

Quoted
prices in active markets

(Level 1)

Significant
other observable inputs

(Level 2)

Significant unobservable
inputs

(Level 3)

Derivative liability ⁽¹⁾

	(1) Derivative liability amounts are due to the embedded derivatives of convertible debenture issued by the Company and are calculated using the Black Scholes pricing model (Note 5).

	The Company has no financial assets carried at fair value.

XML 27 R16.htm IDEA: XBRL DOCUMENT

Subsequent Events

9 Months Ended

Oct. 31, 2016

Notes to Financial Statements

Note 11. Subsequent Events

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on such evaluation, no events occurred that required disclosure.

XML 28 R17.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

9 Months Ended

Oct. 31, 2016

Significant Accounting Policies Policies

Basis of Presentation

The consolidated financial statements and the related notes of the Company are prepared in accordance with generally accepted accounting principles in the United States and are expressed in U.S. dollars. The Company’s fiscal year-end is January 31.

Use of Estimates

The preparation of these consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the useful life and recoverability of long-lived assets, assumptions used to determine the fair values of stock-based compensation and derivative liabilities and deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Interim Financial Statements

These interim unaudited condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s condensed consolidated financial position, results of operations and cash flows for the periods shown. The condensed consolidated results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. Certain disclosures and financial information have been condensed in accordance with generally accepted accounting principles in the United States.

Basis of Consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company. Control is achieved where the Company has the power to govern the financial and operating policies of an entity so as to obtain benefits from its activities. The consolidating entities include:

Loss Per Share

The Company computes net loss per share in accordance with ASC 260, Earnings Per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the consolidated statement of operations. Basic EPS is computed by dividing net income (loss) available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method for all exercisable options and warrants and the if-converted method for all outstanding convertible debentures. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. At October 31, 2016 and 2015, the Company had 8,705,847 and zero potentially dilutive shares, respectively.

Financial Instruments and Fair Value Measures

ASC 820, Fair Value Measurements, requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1: Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial position or results of operations.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Tables)

9 Months Ended

Oct. 31, 2016

Significant Accounting Policies Tables

Basis of Consolidation

XML 30 R19.htm IDEA: XBRL DOCUMENT

Property and Equipment (Tables)

9 Months Ended

Oct. 31, 2016

Property And Equipment Tables

Property and Equipment

Cost

Accumulated amortization

October 31,

2016

Net carrying
value

(unaudited)

January 31,

2016

Net carrying

value

Office furniture and equipment

1,628

–

XML 31 R20.htm IDEA: XBRL DOCUMENT

Derivative Liability (Tables)

9 Months Ended

Oct. 31, 2016

Derivative Liability Tables

Schedule of Fair value of derivative liability

	October 31, 2016 $		January 31, 2016 $

September 2016 convertible debenture		447,115		–

		447,115		–

Schedule of Interest Rate Derivatives

	Expected Volatility			Risk-free Interest Rate			Expected Dividend Yield			Expected Life (in years)
As at issuance date:
September 2016 convertible debenture		296	%		0.45	%		0	%		0.50
As at October 31, 2016:
September 2016 convertible debenture		311	%		0.51	%		0	%		0.41

XML 32 R21.htm IDEA: XBRL DOCUMENT

Stock Options (Tables)

9 Months Ended

Oct. 31, 2016

Stock Options Tables

Schedule of Stock Options

	Number of Options			Weighted Average Exercise Price (US$)			Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value (US$)

Outstanding, January 31, 2015		80,000			0.05			–		–
Granted		6,200,000			0.10			4.1		4,930,000
Expired		(80,000	)		(0.05	)		–		–

Outstanding, January 31, 2016		6,200,000			0.10			4.1		4,930,000
Granted		7,279,000			0.70			4.3		–
Forfeited		(2,000,000	)		(0.10	)		–		–

Outstanding, October 31, 2016		11,479,000			0.48			4.2		36,000

Fair value of stock-based compensation expense

	Expected Volatility			Risk-free Interest Rate			Expected Dividend Yield			Expected Life (in years)
200,000 options expiring on November 30, 2020		400	%		1.16	%		0	%		4.1
7,250,000 options expiring on February 22, 2021		393	%		1.16	%		0	%		4.3
29,000 options expiring on May 2, 2021		393	%		1.16	%		0	%		4.5

Additional information of stock options

Options Outstanding		Option Exercisable		Exercise Price $	Expiry Date

	200,000		100,000	0.25	November 30, 2020
	4,000,000		4,000,000	0.10	December 14, 2020
	7,250,000		5,437,500	0.70	February 22, 2021
	29,000		26,000	0.34	May 2, 2021
	11,479,000		9,563,500

XML 33 R22.htm IDEA: XBRL DOCUMENT

Share Purchase Warrant (Tables)

9 Months Ended

Oct. 31, 2016

Share Purchase Warrant Tables

Schedule of continuity of share purchase warrants

	Number of Warrants		Weighted Average Exercise Price $

Balance, January 31, 2016		–		–

Granted		434,622		0.10
Balance, October 31, 2016		434,622		0.10

Schedule of share purchase warrant was outstanding

Number of
Warrants

Exercise

Price

Expiry Date

434,622

0.10

March 30, 2017

XML 34 R23.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Tables)

9 Months Ended

Oct. 31, 2016

Fair Value Measurements Tables

Fair Value Measurement

	The Company’s financial liabilities carried at fair value measured on a recurring basis as of October 31, 2016 and January 31, 2016, consisted of the following:

Total fair
value at
October 31,
2016

Quoted
prices in
active markets

(Level 1)

Significant
other
observable
inputs

(Level 2)

Significant unobservable
inputs

(Level 3)

Derivative liability ⁽¹⁾

447,115

Total fair
value at
January 31,
2016

Quoted
prices in active markets

(Level 1)

Significant
other observable inputs

(Level 2)

Significant unobservable
inputs

(Level 3)

Derivative liability ⁽¹⁾

XML 35 R24.htm IDEA: XBRL DOCUMENT

Nature of Operations and Continuance of Business (Details Narrative) - USD ($)	Oct. 31, 2016	Jan. 31, 2016
Nature Of Operations And Continuance Of Business Details Narrative
Working capital deficit	$ 1,164,614
Accumulated deficit	$ (19,785,698)	$ (14,319,546)

XML 36 R25.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details)	9 Months Ended
Significant Accounting Policies (Details)	Oct. 31, 2016
Pivot Pharmaceuticals Inc. [Member]
Percentege of ownership	Parent
Jurisdiction	Canada
IndUS Pharmaceuticals, Inc. [Member]
% of ownership	100.00%
Jurisdiction	USA

XML 37 R26.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Details Narrative) - shares	9 Months Ended
	Oct. 31, 2016	Oct. 31, 2015
Significant Accounting Policies Details Narrative
Potentially dilutive shares	8,705,847	0

XML 38 R27.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details) - USD ($)	Oct. 31, 2016	Jan. 31, 2016
Net carrying value
Office furniture and equipment [Member]
Cost	1,628
Accumulated amortization	$ 1,628

XML 39 R28.htm IDEA: XBRL DOCUMENT

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment (Details Narrative) - USD ($)	Oct. 31, 2016	Oct. 31, 2015	Oct. 31, 2016	Oct. 31, 2015
Property And Equipment Details Narrative
Depreciation expense		$ 86		$ 269

XML 40 R29.htm IDEA: XBRL DOCUMENT

Convertible Debenture (Details Narrative) - USD ($)	9 Months Ended
Convertible Debenture (Details Narrative) - USD ($)	Oct. 31, 2016	Sep. 30, 2016	Jan. 31, 2016
Convertible debenture	$ 142,588	$ 380,411
Bears interest per annum		8.00%
Fair value of derivative liability	221,158
Accrued interest	2,533
Derivative liabilities	447,115
Convertible Loan Agreement [Member]
Shares issued to purchase warrants		434,622
Acquired an interest on principal amount		12.00%
Shares price		$ 0.10
Fair Value of warrant	$ 20,154

XML 41 R30.htm IDEA: XBRL DOCUMENT

Derivative Liability (Details) - USD ($)	Oct. 31, 2016	Jan. 31, 2016
Derivative liabilities	$ 447,115
September 2016 Convertible Debenture [Member]
Derivative liabilities	$ 447,115

- Definition

Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

+ References + Details

XML 42 R31.htm IDEA: XBRL DOCUMENT

Derivative Liability (Details 1) - September 2016 Convertible Debenture [Member]	9 Months Ended	12 Months Ended
	Oct. 31, 2016	Jan. 31, 2016
Expected volatility	311.00%	296.00%
Risk-free interest rate	0.51%	0.45%
Expected dividend yield	0.00%	0.00%
Expected life (in years)	4 months 28 days	6 months

XML 43 R32.htm IDEA: XBRL DOCUMENT

Common Stock (Details Narrative) - USD ($)		1 Months Ended
Common Stock (Details Narrative) - USD ($)	Feb. 10, 2016	Jul. 31, 2016	Jun. 30, 2016	Oct. 31, 2016	Aug. 30, 2016	Aug. 02, 2016	Jun. 28, 2016	May 31, 2016	May 02, 2016	Mar. 31, 2016	Feb. 29, 2016	Jan. 31, 2016
Common Stock Details Narrative
Common stock shares issued for compensation					3,250	3,757	4,875	6,000	7,500	13,750	15,000
Common stock, Shares issued				75,622,100	25,000	25,000	25,000	25,000	25,000	25,000	25,000	74,722,100
Common stock shares issued for services, share	100,000		600,000
Common stock shares issued for services,value	$ 68,000		$ 144,500
Common stock shares issued to SAB member,share		25,000
Common stock shares issued to SAB member,value		$ 3,750
Common stock issuable to SAB member				$ 1,697								$ 16,206

XML 44 R33.htm IDEA: XBRL DOCUMENT

Stock Options (Details) - USD ($)	9 Months Ended	12 Months Ended
Stock Options (Details) - USD ($)	Oct. 31, 2016	Jan. 31, 2016
Number of Options
Balance, beginning	6,200,000	80,000
Granted	7,279,000	6,200,000
Expired		(80,000)
Forfeited	(2,000,000)
Balance, ending	11,479,000	6,200,000
Weighted Average Exercise Price
Balance, beginning	$ 0.10	$ 0.05
Granted	0.70	0.10
Expired		(0.05)
Forfeited	(0.10)
Balance, ending	$ 0.48	$ 0.10
Weighted Average Remaining Contractual Life (years)
Granted	4 years 3 months 18 days	4 years 1 month 6 days
Balance, ending	4 years 2 months 12 days	4 years 1 month 6 days
Aggregate Intrinsic Value
Balance, beginning	$ 4,930,000
Granted		$ 4,930,000
Balance, ending	$ 36,000	$ 4,930,000

XML 45 R34.htm IDEA: XBRL DOCUMENT

Stock Options (Details 1)	9 Months Ended
Stock Options (Details 1)	Oct. 31, 2016
200,000 options expiring on November 30, 2020 [Member]
Expected Volatility	400.00%
Risk-free Interest Rate	1.16%
Expected Dividend Yield	0.00%
Expected Life (in years)	4 years 1 month 6 days
7,250,000 options expiring on February 22, 2021 [Member]
Expected Volatility	393.00%
Risk-free Interest Rate	1.16%
Expected Dividend Yield	0.00%
Expected Life (in years)	4 years 3 months 18 days
29,000 options expiring on May 2, 2021 [Member]
Expected Volatility	393.00%
Risk-free Interest Rate	1.16%
Expected Dividend Yield	0.00%
Expected Life (in years)	4 years 6 months

XML 46 R35.htm IDEA: XBRL DOCUMENT

Stock Options (Details 2) - $ / shares	9 Months Ended
Stock Options (Details 2) - $ / shares	Oct. 31, 2016	Jan. 31, 2016	Jan. 31, 2015
Options Outstanding	11,479,000	6,200,000	80,000
Options Exercisable	9,563,500
Exercise Price 0.25 [Member]
Options Outstanding	200,000
Options Exercisable	100,000
Exercise Price	$ 0.25
Expiry Date	Nov. 30, 2020
Exercise Price 0.10 [Member]
Options Outstanding	4,000,000
Options Exercisable	4,000,000
Exercise Price	$ 0.10
Expiry Date	Dec. 14, 2020
Exercise Price 0.70 [Member]
Options Outstanding	7,250,000
Options Exercisable	5,437,500
Exercise Price	$ 0.70
Expiry Date	Feb. 22, 2021
Exercise Price 0.34 [Member]
Options Outstanding	29,000
Options Exercisable	26,000
Exercise Price	$ 0.34
Expiry Date	May 02, 2021

XML 47 R36.htm IDEA: XBRL DOCUMENT

Stock Options (Details Narrative)	9 Months Ended
Stock Options (Details Narrative)	Oct. 31, 2016 USD ($)
Stock Options Details Narrative
Stock-based compensation	$ 83,068

XML 48 R37.htm IDEA: XBRL DOCUMENT

Share Purchase Warrant (Details) - $ / shares	9 Months Ended	12 Months Ended
Share Purchase Warrant (Details) - $ / shares	Oct. 31, 2016	Jan. 31, 2016
Number of Warrants, Granted	7,279,000	6,200,000
Weighted Average Exercise Price, Granted	$ 0.70	$ 0.10
Warrant [Member]
Number of Warrants, Beginning
Number of Warrants, Granted	434,622
Number of Warrants, Ending	434,622
Weighted Average Exercise Price, Beginning
Weighted Average Exercise Price, Granted	0.10
Weighted Average Exercise Price, Ending	$ 0.10

XML 49 R38.htm IDEA: XBRL DOCUMENT

Share Purchase Warrant (Details 1) - Warrant [Member] - $ / shares	9 Months Ended
	Oct. 31, 2016	Jan. 31, 2016
Number of Warrants	434,622
Exercise Price	$ 0.10
Expiry Date	March 30, 2017

XML 50 R39.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Narrative) - USD ($)		1 Months Ended		9 Months Ended
	Feb. 10, 2016	Jun. 30, 2016	Apr. 15, 2015	Oct. 31, 2016	Jan. 31, 2016
Due to related parties				$ 25,972	$ 37,622
Acquisition Agreement date				Nov. 04, 2015
Common stock issued for services	$ 68,000	$ 144,500
Officer [Member]
Shares based compensation expense			$ 191,356
Common stock issued for services			$ 2,000,000
Director [Member]
Due to related parties				$ 4,694	800
CEO [Member]
Due to related parties				16,721	866
Stock Option [Member]
Due to related parties				$ 4,557	$ 37,622

XML 51 R40.htm IDEA: XBRL DOCUMENT

Fair Value Measurements (Details) - USD ($)	Oct. 31, 2016	Jan. 31, 2016
Derivative liability	$ 447,115
Quoted prices in active markets (Level 1) [Member]
Derivative liability
Significant other observable inputs (Level 2) [Member]
Derivative liability	447,115
Significant unobservable inputs (Level 3) [Member]
Derivative liability

EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 56 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 57 140 1 false 20 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://neurokine.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://neurokine.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://neurokine.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://neurokine.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://neurokine.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (unaudited) Statements 5 false false R6.htm 00000006 - Disclosure - Nature of Operations and Continuance of Business Sheet http://neurokine.com/role/NatureOfOperationsAndContinuanceOfBusiness Nature of Operations and Continuance of Business Notes 6 false false R7.htm 00000007 - Disclosure - Significant Accounting Policies Sheet http://neurokine.com/role/SignificantAccountingPolicies Significant Accounting Policies Notes 7 false false R8.htm 00000008 - Disclosure - Property and Equipment Sheet http://neurokine.com/role/PropertyAndEquipment Property and Equipment Notes 8 false false R9.htm 00000009 - Disclosure - Convertible Debenture Sheet http://neurokine.com/role/ConvertibleDebenture Convertible Debenture Notes 9 false false R10.htm 00000010 - Disclosure - Derivative Liability Sheet http://neurokine.com/role/DerivativeLiability Derivative Liability Notes 10 false false R11.htm 00000011 - Disclosure - Common Stock Sheet http://neurokine.com/role/CommonStock Common Stock Notes 11 false false R12.htm 00000012 - Disclosure - Stock Options Sheet http://neurokine.com/role/StockOptions Stock Options Notes 12 false false R13.htm 00000013 - Disclosure - Share Purchase Warrant Sheet http://neurokine.com/role/SharePurchaseWarrant Share Purchase Warrant Notes 13 false false R14.htm 00000014 - Disclosure - Related Party Transactions Sheet http://neurokine.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 00000015 - Disclosure - Fair Value Measurements Sheet http://neurokine.com/role/FairValueMeasurements Fair Value Measurements Notes 15 false false R16.htm 00000016 - Disclosure - Subsequent Events Sheet http://neurokine.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 00000017 - Disclosure - Significant Accounting Policies (Policies) Sheet http://neurokine.com/role/SignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://neurokine.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Significant Accounting Policies (Tables) Sheet http://neurokine.com/role/SignificantAccountingPoliciesTables Significant Accounting Policies (Tables) Tables http://neurokine.com/role/SignificantAccountingPolicies 18 false false R19.htm 00000019 - Disclosure - Property and Equipment (Tables) Sheet http://neurokine.com/role/PropertyAndEquipmentTables Property and Equipment (Tables) Tables http://neurokine.com/role/PropertyAndEquipment 19 false false R20.htm 00000020 - Disclosure - Derivative Liability (Tables) Sheet http://neurokine.com/role/DerivativeLiabilityTables Derivative Liability (Tables) Tables http://neurokine.com/role/DerivativeLiability 20 false false R21.htm 00000021 - Disclosure - Stock Options (Tables) Sheet http://neurokine.com/role/StockOptionsTables Stock Options (Tables) Tables http://neurokine.com/role/StockOptions 21 false false R22.htm 00000022 - Disclosure - Share Purchase Warrant (Tables) Sheet http://neurokine.com/role/SharePurchaseWarrantTables Share Purchase Warrant (Tables) Tables http://neurokine.com/role/SharePurchaseWarrant 22 false false R23.htm 00000023 - Disclosure - Fair Value Measurements (Tables) Sheet http://neurokine.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://neurokine.com/role/FairValueMeasurements 23 false false R24.htm 00000024 - Disclosure - Nature of Operations and Continuance of Business (Details Narrative) Sheet http://neurokine.com/role/NatureOfOperationsAndContinuanceOfBusinessDetailsNarrative Nature of Operations and Continuance of Business (Details Narrative) Details http://neurokine.com/role/NatureOfOperationsAndContinuanceOfBusiness 24 false false R25.htm 00000025 - Disclosure - Significant Accounting Policies (Details) Sheet http://neurokine.com/role/SignificantAccountingPoliciesDetails Significant Accounting Policies (Details) Details http://neurokine.com/role/SignificantAccountingPoliciesTables 25 false false R26.htm 00000026 - Disclosure - Significant Accounting Policies (Details Narrative) Sheet http://neurokine.com/role/SignificantAccountingPoliciesDetailsNarrative Significant Accounting Policies (Details Narrative) Details http://neurokine.com/role/SignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - Property and Equipment (Details) Sheet http://neurokine.com/role/PropertyAndEquipmentDetails Property and Equipment (Details) Details http://neurokine.com/role/PropertyAndEquipmentTables 27 false false R28.htm 00000028 - Disclosure - Property and Equipment (Details Narrative) Sheet http://neurokine.com/role/PropertyAndEquipmentDetailsNarrative Property and Equipment (Details Narrative) Details http://neurokine.com/role/PropertyAndEquipmentTables 28 false false R29.htm 00000029 - Disclosure - Convertible Debenture (Details Narrative) Sheet http://neurokine.com/role/ConvertibleDebentureDetailsNarrative Convertible Debenture (Details Narrative) Details http://neurokine.com/role/ConvertibleDebenture 29 false false R30.htm 00000030 - Disclosure - Derivative Liability (Details) Sheet http://neurokine.com/role/DerivativeLiabilityDetails Derivative Liability (Details) Details http://neurokine.com/role/DerivativeLiabilityTables 30 false false R31.htm 00000031 - Disclosure - Derivative Liability (Details 1) Sheet http://neurokine.com/role/DerivativeLiabilityDetails1 Derivative Liability (Details 1) Details http://neurokine.com/role/DerivativeLiabilityTables 31 false false R32.htm 00000032 - Disclosure - Common Stock (Details Narrative) Sheet http://neurokine.com/role/CommonStockDetailsNarrative Common Stock (Details Narrative) Details http://neurokine.com/role/CommonStock 32 false false R33.htm 00000033 - Disclosure - Stock Options (Details) Sheet http://neurokine.com/role/StockOptionsDetails Stock Options (Details) Details http://neurokine.com/role/StockOptionsTables 33 false false R34.htm 00000034 - Disclosure - Stock Options (Details 1) Sheet http://neurokine.com/role/StockOptionsDetails1 Stock Options (Details 1) Details http://neurokine.com/role/StockOptionsTables 34 false false R35.htm 00000035 - Disclosure - Stock Options (Details 2) Sheet http://neurokine.com/role/StockOptionsDetails2 Stock Options (Details 2) Details http://neurokine.com/role/StockOptionsTables 35 false false R36.htm 00000036 - Disclosure - Stock Options (Details Narrative) Sheet http://neurokine.com/role/StockOptionsDetailsNarrative Stock Options (Details Narrative) Details http://neurokine.com/role/StockOptionsTables 36 false false R37.htm 00000037 - Disclosure - Share Purchase Warrant (Details) Sheet http://neurokine.com/role/SharePurchaseWarrantDetails Share Purchase Warrant (Details) Details http://neurokine.com/role/SharePurchaseWarrantTables 37 false false R38.htm 00000038 - Disclosure - Share Purchase Warrant (Details 1) Sheet http://neurokine.com/role/SharePurchaseWarrantDetails1 Share Purchase Warrant (Details 1) Details http://neurokine.com/role/SharePurchaseWarrantTables 38 false false R39.htm 00000039 - Disclosure - Related Party Transactions (Details Narrative) Sheet http://neurokine.com/role/RelatedPartyTransactionsDetailsNarrative Related Party Transactions (Details Narrative) Details http://neurokine.com/role/RelatedPartyTransactions 39 false false R40.htm 00000040 - Disclosure - Fair Value Measurements (Details) Sheet http://neurokine.com/role/FairValueMeasurementsDetails Fair Value Measurements (Details) Details http://neurokine.com/role/FairValueMeasurementsTables 40 false false All Reports Book All Reports pvotf-20161031.xml pvotf-20161031.xsd pvotf-20161031_cal.xml pvotf-20161031_def.xml pvotf-20161031_lab.xml pvotf-20161031_pre.xml true true ZIP 58 0001477932-16-014025-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-16-014025-xbrl.zip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end

British Columbia		N/A
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

1275 West 6th Avenue, Vancouver, British Columbia, Canada				V6H 1A6
(Address of principal executive offices)				(Zip Code)

Large accelerated filer	o	Accelerated filer	o
Non-accelerated filer	o	Smaller reporting company	x
(Do not check if a smaller reporting company)

PART I – FINANCIAL INFORMATION

Item 1.	Financial Statements.	3

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations.	15

Item 3.	Quantitative and Qualitative Disclosure About Market Risk.	23

Item 4.	Controls and Procedures.	23

PART II – OTHER INFORMATION

Item 1.	Legal Proceedings.	24

Item 1A.	Risk Factors.	24

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	24

Item 3.	Defaults Upon Senior Securities.	24

Item 4.	Mine Safety Disclosures.	24

Item 5.	Other Information.	24

Item 6.	Exhibits.	25

SIGNATURES.		27

	October 31, 2016 $			January 31, 2016 $
	(unaudited)
Assets

Current assets

Cash		206,575			71,639
Prepaid and other current assets		19,211			31,576
Total current assets		225,786			103,215
Security deposit		2,900			2,900
Total assets		228,686			106,115

Liabilities and Stockholders’ Deficit

Current liabilities
Accounts payable and accrued liabilities		774,725			397,482
Due to related parties (Note 9)		25,972			37,622
Convertible debenture, net of discount (Note 4)		142,588			–
Derivative liability (Note 5)		447,115			–
Total liabilities		1,390,400			435,104

Stockholders’ Deficit

Common stock: Unlimited shares authorized, without par value, 75,622,100 and 74,722,100 shares issued and outstanding, respectively		7,324,881			7,054,499

Common stock issuable (Note 6)		1,697			16,206

Additional paid-in capital		10,661,752			6,174,601

Accumulated other comprehensive income		635,654			745,251

Accumulated deficit		(19,785,698	)		(14,319,546	)

Total stockholders’ deficit		(1,161,714	)		(328,989	)

Total liabilities and stockholders’ deficit		228,686			106,115

	Three Months Ended October 31, 2016 $			Three Months Ended October 31, 2015 $			Nine Months Ended October 31, 2016 $			Nine Months Ended October 31, 2015 $
	(unaudited)			(unaudited)			(unaudited)			(unaudited)

Revenue		–			–			–			–

Expenses

Depreciation and amortization		–			86			–			269
Foreign exchange loss		60,658			4,367			138,017			8,733
General and administrative		71,301			(8,264	)		1,045,722			866,505
Management fees (Note 9)		548,407			(116,405	)		3,917,354			2,298,813
Professional fees		9,938			128,058			100,421			355,727

Total expenses		690,304			7,842			5,201,514			3,530,047

Loss from operations		(690,304	)		(7,842	)		(5,201,514	)		(3,530,047	)

Other income (expense)

Amortization of discount on convertible debenture		(48,672	)		–			(48,672	)		–
Interest expense		(3,612	)		–			(3,612	)		–
(Loss) gain on change in fair value of derivative liabilities		(212,354	)		–			(212,354	)		14,958

Total other income (expense)		(264,638	)		–			(264,638	)		14,958

Net loss		(954,942	)		(7,842	)		(5,466,152	)		(3,515,089	)

Other comprehensive income (loss)

Foreign currency translation adjustment		(40,569	)		142,447			109,597			(261,299	)

Net comprehensive income (loss)		(995,511	)		134,605			(5,356,555	)		(3,776,388	)

Net loss per share, basic and diluted		(0.01	)		(0.00	)		(0.07	)		(0.05	)

Weighted average shares outstanding – basic and diluted		75,613,498			85,570,289			75,212,555			76,886,477

4.	Convertible Debenture (continued)

	As of October 31, 2016, the carrying value of the convertible debenture is $191,215 Canadian Dollars ($142,588 US Dollars at October 31, 2016) (January 31, 2016 - $nil) with accrued interest $2,533 (January 31, 2016 - $nil). As of October 31, 2016, the fair value of the conversion option derivative liability is $447,115 (January 31, 2016 - $nil).

5.	Derivative Liability

	Derivative liability consists of convertible debenture with variable conversion price (Note 4). The fair value of derivative liability as at October 31, 2016 and January 31, 2016 is as follows:

	Expected Volatility			Risk-free Interest Rate			Expected Dividend Yield			Expected Life (in years)
As at issuance date:
September 2016 convertible debenture		296	%		0.45	%		0	%		0.50
As at October 31, 2016:
September 2016 convertible debenture		311	%		0.51	%		0	%		0.41

	Number of Options			Weighted Average Exercise Price (US$)			Weighted Average Remaining Contractual Life (years)		Aggregate Intrinsic Value (US$)

Outstanding, January 31, 2015		80,000			0.05			–		–
Granted		6,200,000			0.10			4.1		4,930,000
Expired		(80,000	)		(0.05	)		–		–

Outstanding, January 31, 2016		6,200,000			0.10			4.1		4,930,000
Granted		7,279,000			0.70			4.3		–
Forfeited		(2,000,000	)		(0.10	)		–		–

Outstanding, October 31, 2016		11,479,000			0.48			4.2		36,000

Options Outstanding		Option Exercisable		Exercise Price $	Expiry Date

	200,000		100,000	0.25	November 30, 2020
	4,000,000		4,000,000	0.10	December 14, 2020
	7,250,000		5,437,500	0.70	February 22, 2021
	29,000		26,000	0.34	May 2, 2021
	11,479,000		9,563,500

	Number of Warrants		Weighted Average Exercise Price $

Balance, January 31, 2016		–		–

Granted		434,622		0.10
Balance, October 31, 2016		434,622		0.10

10.	Fair Value Measurements

	The Company’s financial liabilities carried at fair value measured on a recurring basis as of October 31, 2016 and January 31, 2016, consisted of the following:

11.	Subsequent Events

	Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on such evaluation, no events occurred that required disclosure.

	·	identifying novel drug delivery technologies that will allow targeted drug delivery for drugs;
	·	securing and developing intellectual property rights to such products;
	·	conducting appropriate laboratory tests and clinical trials;
	·	advancing novel drug candidates to treat women’s cancers from our acquisition of IndUS to support Investigational New Drug application to allow first-in-human trials;
	·	opportunistically acquiring later-stage drug candidates that provide new treatment options to address unmet medical needs in women’s health in cancer and lower urinary tract symptoms; and
	·	establishing partnerships with large and specialty pharmaceutical companies and/or biotechnology companies to collaboratively develop and/or commercialize our products.

	·	Metastatic endometrial cancer (PVT-005)
	·	Triple-negative breast cancer (PVT-006)
	·	Lower urinary tract symptoms including filling and voiding issues (PVT-002)

	Three Months Ended						Nine Months Ended
	October 31,						October 31,
	2016			2015			2016			2015

Revenue	$	Nil		$	Nil		$	Nil		$	Nil
Depreciation	$	Nil		$	86		$	Nil		$	269
Foreign exchange (gain) loss	$	60,658		$	4,367		$	138,017		$	8,733
General and administrative	$	71,301		$	(8,264	)	$	1,045,722		$	866,505
Management fees	$	548,407		$	(116,405	)	$	3,917,354		$	2,298,813
Professional fees	$	9,938		$	128,058		$	100,421		$	355,727
Total Other (Income) Expenses	$	264,638		$	-		$	264,638		$	(14,958	)
Net Income (Loss)	$	(954,942	)	$	(7,842	)	$	(5,466,152	)	$	(3,515,089	)

	Estimated Expenses
Description	($)
Research and Development Costs:
Studies and manufacture of active product ingredient		5,125,000
IND filing		1,000,000
R&D headcount		1,250,000
Sales and Marketing Costs:
Entertainment and promotion		24,000
Investor relations		60,000
Literature		11,600
Travel		60,000
Operating Expenses:
Director fees		160,000
Insurance		40,000
Office		21,200
Office and laboratory lease		30,000
Professional fees		143,000
Public company expenses		52,500
Salaries and benefits		898,523
Telephone and internet		6,000
Vehicles and transportation		6,000
Total:		8,887,823

Exhibit Number	Description

(3)	Articles of Incorporation and Bylaws
3.1	Articles of Incorporation 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.2	“Company Act” Memorandum of 649186 B.C. Ltd. Certificate of Amendment (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.3	Certificate of Filing of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.4	Certificate of Incorporation of 649186 B.C. Ltd. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.5	Certificate of Name Change of 649186 B.C. Ltd. to Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.6	Transition Application of Xerxes Health Corp. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.7	Certificate of Name Change of Xerxes Health Corp. to Neurokine Pharmaceuticals Inc. (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.8	Notice of Alteration to Authorized Share Structure (incorporated by reference from our Registration Statement on Form S-1 filed on August 7, 2009)
3.9	Notice of Alteration to Authorized Share Structure (incorporated by reference from our Current Report on Form 8-K filed on June 4, 2014)
3.10	Form 11 Notice of Alteration (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)
3.11	Articles (incorporated by reference from our Current Report on Form 8-K filed on October 9, 2014)
3.12		Notice of Alteration changing name to Pivot Pharmaceuticals Inc. (incorporated by reference to our Current Report on Form 8-K filed on April 17, 2015)
3.13		Certificate of Name Change of Neurokine Pharmaceuticals Inc. to Pivot Pharmaceuticals Inc.
(10)	Material Contracts
10.1	Non-Exclusive License Agreement with Globe Laboratories Inc. dated June 17, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.2	Clinical Trial Services Agreement with Virtus Clinical Development (Pty) Limited dated March 1, 2009 (incorporated by reference to our Registration Statement on Form S-1/A filed on March 4, 2010)
10.3	Master Service Agreement with Northern Lipids Inc. dated October 2, 2007 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.4	Assignment of Invention (NK-001) dated January 30, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.5	Assignment of Invention (NK-002) dated April 18, 2008 (incorporated by reference to our Registration Statement on Form S-1/A filed on December 3, 2009)
10.6	Subscription Agreement with Ahmad Doroudian (incorporated by reference to our Form 8-K filed on August 12, 2010)
10.7	Debt Settlement Subscription Agreement dated September 26, 2013 with Ahmad Doroudian (incorporated by reference to our Quarterly Report on Form 10-Q filed on December 16, 2013)

10.8		Director Services Agreement dated February 25, 2015 with Barbara-Jean Bormann-Kennedy (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.9		Director Services Agreement dated February 25, 2015 with Dr. Patrick Frankham (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.10		Director Services Agreement dated February 26, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.11		Consulting Services Agreement dated February 25, 2015 with Dr. Giora Davidai (incorporated by reference to our Current Report on Form 8-K filed on March 26, 2015)
10.12		Director Services Agreement dated November 19, 2015 with Dr. Patrick Frankham (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.13		Director Services Agreement dated November 19, 2015 with Dr. Wolfgang Renz (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.14		Consulting Services Agreement dated November 19, 2015 with Dr. Giora Davidai (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.15		Plan of Merger and Acquisition Agreement between our company and IndUS Pharmaceuticals, Inc., dated November 4, 2015 (incorporated by reference to our Current Report on Form 8 K filed on November 23, 2015 and our Current Report on Form 8 K/A filed on February 3, 2016)
10.16		Employment Agreement dated November 20, 2015 with Dr. Pravin Chaturvedi (incorporated by reference to our Quarterly Report on Form 10 Q filed on December 15, 2015)
10.17		Employment Agreement dated February 1, 2016 with Dr. Ahmad Doroudian
10.18		Employment Agreement dated February 1, 2016 with Moira Ong
10.19		Consulting Services Agreement dated February 1, 2016 with Soho Capital Inc.
(31)	Rule 13a-14(d)/15d-14(d) Certifications
31.1*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer
31.2*	Section 302 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer
(32)	Section 1350 Certifications
32.1*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Executive Officer
32.2*	Section 906 Certification under the Sarbanes-Oxley Act of 2002 of Principal Financial Officer
99		Additional Exhibits
99.1		Audit Committee Charter
99.2		Stock Option Plan
101*	Interactive Data Files
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document
101.LAB	XBRL Taxonomy Extension Label Linkbase Document
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document

		PIVOT PHARMACEUTICALS INC.
		(Registrant)

Dated: December 9, 2016		/s/ Pravin Chaturvedi
		Dr. Pravin Chaturvedi
		Chief Executive Officer and Director
		(Principal Executive Officer)

Dated: December 9, 2016		/s/ Moira Ong
		Moira Ong
		Chief Financial Officer
		(Principal Financial Officer and Principal Accounting Officer)

1.	I have reviewed this quarterly report on Form 10-Q of Pivot Pharmaceuticals Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	(c)	Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	(d)	Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

	(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

	(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: December 9, 2016		/s/ Pravin Chaturvedi
		Pravin Chaturvedi
		Chief Executive Officer and Director (Principal Executive Officer)

(1)	the Quarterly Report on Form 10-Q of Pivot Pharmaceuticals Inc. for the period ended October 31, 2016 (the "Report") fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Pivot Pharmaceuticals Inc.